roche annual report finance report part innovate healthcareinnovative solutions spanning healthcare spectrum combined capabilities diagnostics pharmaceuticals enable us meet needs across entire healthcare spectrum identifying disease suscep tibilities screening disease atrisk populations prevention diagnosis therapy treatment monitoring innovative products advancing fight disease wide range fronts making real difference patients health professionals roche commitment innovating healthcare matched commitment corporate social responsibility sustainability one companys guiding values recognise economic social environmental concerns inter twined progress sectors requires progress three researchintensive company longterm strategic focus roche strives deliver sustainable value major stakeholderstable contents finance report roche group finance brief finance brief financial review operating results nonoperating results cash flows net cash balance sheet roche securities financial risks international financial reporting standards roche group consolidated financial statements income statement balance sheet cash flow statement statement recognised income expense statement changes equity notes roche group consolidated financial statements report group auditors multiyear overview supplementary net income eps information roche securities roche holding ltd basel financial statements income statement balance sheet notes financial statements appropriation available earnings report statutory auditors finance report finance brief key results operating profit margin exceptional items local sales growth sales pharmaceuticals diagnostics group change sales mchf mchf chf lc sales ebitda operating profit exceptional items profit exceptional items net income net cash equity equity ratio core eps dividend per share continuing businesses ebitda earnings exceptional items financial income financing costs tax depreciation amortisation including impairment corresponds operating profit exceptional items depreciation amorti sation including impairment see definition core eps proposed board directors lc local currencies finance executive team erich hunziker chief financial officer paul de wouters management development peter eisenring taxes insurances marco frei pension asset management andreas knierzinger treasury steve krognes corporate development karl mahler investor relations erwin schneider accounting controlling finance report finance brief sales record sales pharmaceuticals diagnostics increase local currencies billion swiss francs oncology sales increased local currencies billion swiss francs sales top product mabtherarituxan billion swiss francs herceptin sales billion swiss francs avastin achieved sales billion swiss francs first full year market tamiflu sales reached billion swiss francs due pandemic stockpiling regular commercial sales operating results increased operating profit exceptional items local currencies billion swiss francs improved profitability operating profit margin exceptional items percentage points investments rd manufacturing facilities cash flow operating activities taxes increased billion swiss francs treasury operations positive net financial income million swiss francs compared net expense million swiss francs rating process finalised roche awarded aa rating moodys aa rating standardpoors reduction corporate debt billion swiss francs bonds repaid first public debt offering genentech partly used restructure existing finance leases financial condition increase net cash billion swiss francs billion swiss francs increase equity ratio decrease debtequity ratio net income decrease overall net income compared billion swiss francs results include billion swiss francs divested consumer health otc business increase profit continuing businesses exceptional items billion swiss francs shareholder returns increase share price swiss francs increase nonvoting equity security price swiss francs increase market capitalisation billion swiss francs increase eps core swiss francs increase proposed dividend swiss francs finance report roche group financial review operating results group operating results sales continuing businesses operating profit exceptional items billions chf lc growth billions chf sales annual results show strong operating performance terms topline growth well profit margins mainly driven pharmaceuticals division total sales grew local currencies swiss francs us dollars billion swiss francs pharmaceuticals division contributing group sales diagnostics division representing incremental sales increase billion swiss francs achieved organic growth primarily driven strong demand groups oncology drugs avastin mabtherarituxan herceptin antiinfluenza drug tamiflu absolute terms increase sales avastin compensated marked decline rocephin sales following patent expiry united states july groups operating profit exceptional items increased billion swiss francs corresponding operating profit margin increased percentage points mainly result strong sales growth margin increase achieved time divisions continued increase investments launch prelaunch activities well strong development pipeline addition gains product divestments million swiss francs lower reporting costs groups equity compensation plans employees operating expenses significant overall impact increasing costs compensated improved underlying results excluding equity compensation plan costs genentech far largest plan group group operating profit margin exceptional items would exchange rate impact sales operating profit growth minor average exchange rates us dollar euro basically levels japanese yen lower average compared finance report roche group financial review group operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales operating profit exceptional items margin ebitda margin group operating results development results compared pharmaceuticals diagnostics corporate group sales increase local currencies operating profit exceptional items increase local currencies margin percentage point increase ebitda increase local currencies margin percentage point increase pharmaceuticals operating results pharmaceuticals division increased sales strongly local currencies swiss francs us dollars billion swiss francs outpacing global market growth four times operating profit exceptional items billion swiss francs representing growth consequently amargin increase percentage points marketing support significant important products mabtherarituxan herceptin avastin pegasyscopegus launch prelaunch activities notably tarceva boniva also significant continued investment strong development pipeline pharmaceuticals subdivisions roche pharmaceuticals genentech chugai contributed improved operating results excluding equity compensation plan costs genentech pharmaceuticals operating profit margin exceptional items would genentechs operating profit margin exceptional items would pharmaceuticals division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items margin ebitda margin sales major growth drivers key products oncology transplantation virology franchises including tamiflu franchises significantly outpacing respective markets renal anemia franchise grew modestly slight decline finance report roche group financial review pharmaceuticals division sales franchises sales change franchise mchf sales local currencies oncology transplantation virology renal anemia others total excluding tamiflu almost product lines showed sales growth especially notable top pharmaceuticals products strong growth top products grew top products two rocephin dilatrend decline due patent expiry respectively growth profitability pharmaceuticals division primarily due eleven products tamiflu avastin mabtherarituxan herceptin tarceva cellcept xeloda pegasyscopegus xolair neorecormonepogin representing portfolio together generated billion swiss francs additional sales pharmaceuticals division sales top products change sales local mchf sales currencies franchise mabtherarituxan oncology neorecormonepogin anemia oncology herceptin oncology cellcept transplantation avastin oncology tamiflu virology pegasys virology rocephin infectious diseases xeloda oncology xenical metabolic disorders kytril oncology nutropinprotropin metabolic disorders xolair respiratory diseases copegus virology cymevenevalcyte transplantation pulmozyme respiratory diseases tarceva oncology neutrogin oncology dilatrend cardiovascular diseases activasetnkase cardiovascular diseases total top products products total mabtherarituxan increase primarily driven higher mabthera sales volumes markets europe rest world due increased market penetration indolent aggressive non hodgkins lymphoma application expand products indications include maintenance treatment indolent nonhodgkins lymphoma filed eu december planned finance report roche group financial review neorecormonepogin sales growth europe mainly driven increased use oncology setting weekly iu prefilled syringe compensated continued price erosion renal anemia indications neorecormon sales oncology increased compared market growth japan epogin grown line market herceptin growth strong us europe driven extension treatment duration increased firstline penetration addition clinical data showing significant efficacy adjuvant breast cancer led growing adoption unapproved area group plans file indication first quarter cellcept growth supported regions cellcept continued clear market leader mycophenolic acid mpa market market share avastin sales growth driven strong increasing uptake treatment colorectal cancer firstline relapsedrefractory settings following approval eu january avastin launched key countries germany major sales contributor group plans filings extend eu label match us label along filings metastatic nonsmall cell lung cancer nsclc metastatic breast cancer based excellent clinical data received earlier year tamiflu sales driven pandemic stockpiling governments sales along commercial seasonal sales sales end countries placed orders pandemic supplies delivery spread revenue tamiflu pandemic contracts recognised risks rewards ownership product transferred customer delivery customer case billandhold arrangements prior final delivery customer inventory specifically identified ready delivery used delivery customers pegasyscopegus pegasys share global pegylated interferon market sales increase drivenby higher pegasys sales volumes european markets due market share increase market expansion based new indications hepatitis b virus normal alt coinfection hiv us sales increased modestly including singledigit price increase marketing application combined pegasys andcopegus hepatitis c designated priority review japanese regulatory agency mhlw xeloda continued growth achieved regions primarily driven obtaining approval new indication adjuvant monotherapy treatment colon cancer received eu april us june xolair sales growth driven increase patient prescriber base extent price increase effective july xolair humanized antiige antibody approved treatment moderatetosevere persistent allergic asthma adults adolescents tarceva major contributor sales us tarceva approved november treatment patients locally advanced metastatic nonsmall cell lung cancer nsclc failure atleast one prior chemotherapy regimen swiss canadian approvals received march july respectively european approval received september tarceva since launched ingermany france uk tarceva launched eu countries reimbursement approvals us food drug administration fda approved tarceva treatment inoperable metastatic pancreatic cancer november roche filed application indication eu regulators october rocephin expected sales declined markedly following expiry products us patent july information products pipeline found appropriate sections business report finance report roche group financial review sales region sales continued grow major regions north america sales grew five times faster market driven products marketed genentech avastin mabtherarituxan herceptin tarceva xolair well tamiflu cellcept xeloda together compensated million swiss francs decline sales rocephin following us patent expiry july europe group continued gain market share driven continuing strong sales growth tamiflu mabtherarituxan herceptin avastin pegasys neorecormon xeloda cellcept sales growth japan primarily driven tamiflu due late severe influenza season early influenza season well neutrogin epogin herceptin pegasys overall sales japan grew close three times faster japanese market pharmaceuticals division sales regions sales change region mchf sales local currencies north america europe japan regions total royalties operating incomethe decrease due lower gains product divestments million swiss francs compared million swiss francs included disposal soriatane partly offset higher royalty income notably genentech due new licence arrangement imclone sales erbitux included within onetime payment relating royalties erbitux sales launch product signing agreement january royalty income genentech also increased due higher sales various licensees products also higher outlicensing income roche pharmaceuticals particular milestone income following fda approval boniva united states cost sales increase local currencies line increase sales due economies scale production including benefits focussing smaller number production sites continuing productivity improvements product mix effects factors compensated increase royalty expenses product sales million swiss francs million swiss francs driven success products mabtherarituxan tarceva xolair particular tamiflu marketing distributionthese costs increased local currencies lower growth sales even taking account ongoing strong support established products global launch activities newly launched products avastin tarceva boniva prelaunch costs products mabtherarituxan rheumatoid arthritis lucentis marketing distribution percentage sales declined percentage points compared research developmentthe increase million swiss francs local currencies almost billion swiss francs reflects ongoing clinical development product pipeline higher expenses earlystage projects research development costs percentage sales percentage points ratio comparative period included substantial amount inlicensing latestage development commercialisation jtt japan tobaccos innovative cholesteryl ester transfer protein cetp inhibitor treatment dyslipidemia finance report roche group financial review general administrationthe overall increase million swiss francs local currencies due several items gilead retrospective adjustments relating higher sap implementation costs genentech charitable contribution genentech lower gains disposal property plant equipment transition impacts expensing equity compensation plans genentech higher restructuring costs roche pharmaceuticals chugai contributed two three percentage points growth excluding items general administration costs grew less growth sales increase driven creation new businesses eastern europe roche pharmaceuticals alignment infrastructure genentech arising continuing strong growth business amortisation impairment intangible assets decline solely due genentech firstly intangible assets fully amortised mid others mid secondly genentech decided stop commercialisation nutropin depot resulted impairment nutropin depot intangible assets million swiss francs thirdly genentech impaired inlicensed compound million swiss francs pharmaceuticals subdivisional results operating operating profit profit exceptional exceptional sales ebitda ebitda items items mchf mchf sales mchf sales roche pharmaceuticals genentech chugai pharmaceuticals division roche pharmaceuticals genentech chugai pharmaceuticals division overall pharmaceuticals division showed strong sales increases subdivisions resulted improved operating margins margin genentech adversely impacted expensing employee stock options excluding margin would increased percentage points chugai improved sales performance particularly tamiflu beneficial impacts overall cost structure following chugais early retirement plan implemented second half main drivers margin improvement additional information pharmaceuticals divisions subdivisional results given note consolidated financial statements information genentech chugai given notes diagnostics operating results diagnostics division increased sales billion swiss francs growing local currencies swiss francs us dollars maintaining leading market position operating profit exceptional items decreased local currencies billion swiss francs margin still well industry average although margin decline percentage points primarily dueto heavy price pressure market additionally higher relative cost sales growth driven startup costs new manufacturing facilities new products well higher depreciation increased volume instrument placements finance report roche group financial review diagnostics division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items margin ebitda margin sales major drivers sales growth centralized diagnostics immunochemistry molecular diagnostics number key diagnostics products launched helped contribute slightly increased growth second half included launch complete new product portfolio diabetes care innovative product offerings new market segments dna sequencing diagnostics division sales business area sales change business area mchf sales local currencies diabetes care centralized diagnostics immunochemistry molecular diagnostics near patient testing applied science total diabetes care diabetes care maintained number one position sales blood glucose monitoring meters strips lancets increasing local currencies billion swiss francs insulin delivery sales grew million swiss francs exception us growth stronger second half due launching five new products completely rejuvenated accuchek portfolio new accuchek aviva meter completed global launching october track reverse market share decline maturation accuchek advantage line accuchek compact plus remains meter market integrating measuring test strip lancet one device rapidly growing new segment rollout nearly complete us launch planned first quarter global launch accuchek multiclix incorporating six lancets almost complete strengthens groups range area insulin delivery group increased market share germany following successful launch accuchek spirit pump accuchek flexlink infusion set us business area ready launch new insulin pumps customers soon food drug administration fda provides goahead centralized diagnostics sales increased local currencies billion swiss francs despite ongoing price pressure laboratory segment immunochemistry sales increased billion swiss francs placements elecsys e platforms increased due aggressive placement strategy increasing demand cardiac test elecsys probnp although clinical chemistry affected pricing pressures business area assumed market leadership clinical laboratory segment third quarter finance report roche group financial review molecular diagnostics blood screening continued provide majority growth increase local currencies million swiss francs due decreased pool size japan combined two german red cross centres korea coming online additionally fda clearance cobas ampliscreen hbv test screening blood plasma ampliscreen hiv hbv hcv tests expanded use screening living cadaveric organ tissue donations sales virology grew local currencies million swiss francs supported introduction new fully automated platforms helped maintain market share overcome pricing pressures near patient testing coagulation sales increased local currencies million swiss francs due increasing adoption testing doctors offices us along growing trend towards patient self monitoring blood gaselectrolytes sales rose local currencies million swiss francs due strong placements blood gaselectrolyte instruments particularly japan latin america sales cardiac reader grew local currencies million swiss francs launch cardiac ntprobnp test second half starting impact introduction new selfcoagulation monitoring device coaguchek xs commenced pilot countries third quarter applied science life science market grew however due strong competitive environment business area sales experienced slightly lower growth year saw number major product launches particularly launch new highthroughput lightcycler system entrance first time profitable dna sequencing market launch genome sequencer system exclusive distribution agreement life sciences sales regions sales continued grow ahead local market regions exception north america sales declined slightly sales region primarily affected declining sales diabetes care roche became leading diagnostics supplier japan diagnostics division sales regions sales change region mchf sales local currencies north america emea japan regions total europe middle east africa excl iberia royalties operating income million swiss francs royalty operating income remained basically levels however royalty income alone declined million swiss francsdue expiry foundational pcr patents substantial oneoff royalty income bioveris million swiss francs comparative period side outlicensing income million swiss francs mainly contracts companies applera abbott genprobe molecular diagnostics compensated decline royalty income cost sales overall increase local currencies sales growth costs goods sold increased rate twice high sales addition heavy selling price pressure production startup costs many new products also new molecular diagnostics manufacturing facility branchburg us furthermore production costs higher products enhanced customer features higher depreciation higher volume instrument placements regulatory compliance costs also increased royalty expenses million swiss francs lower million swiss francs compared due absence royalties paid igen igen acquired group finance report roche group financial review marketing distribution increase local currencies slightly increase sales dueto launch number new diabetes care products accuchek aviva blood glucose meter europe us marketing distribution percentage sales remained stable research development costs grew local currencies less sales major projects coaguchek xs accuchek aviva research development cost peaks percentage sales research development costs declined slightly percentage points general administration costs decreased local currencies due strict cost control lower sap implementation costs amortisation impairment intangible assets increase partially due amortisation intangible assets acquired igen acquisition results include charge million swiss francs compared million swiss francs representing months since acquisition march amortisation expenses recently acquired licence distribution rights account rest increase corporate operating costs general administration costs declined million swiss francs million swiss francs included results gain million swiss francs return part chugais welfare pension fund japanese government november results included million swiss francs administration costs previously allocated consumer health otc business items transferred sale business therefore reclassified business segment corporate costs either restructured away absorbed business segments roche pharmaceuticals chugai exceptional operating items exceptional operating items pharmaceuticals diagnostics corporate group mchf mchf mchf mchf mchf mchf mchf mchf operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit amortisation goodwill following changes international financial reporting standards amortisation goodwill ceased effective january impairments goodwill recorded major legal cases provisions certain litigation arbitration matters pharmaceuticals division increased million swiss francs diagnostics division million swiss francs provisions recorded based current litigation settlement negotiations recent settlement agreements additional information given note consolidated financial statements changes group organisation significant developments additional income expenses recorded operating profit increase million swiss francs local currencies reflects continued improvement groups operating performance lower exceptional items driven amortisation goodwill finance report roche group financial review nonoperating results nonoperating results change mchf mchf chf operating profit associated companies financial income financing costs exceptional income bond conversion redemption profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests groups treasury operations delivered positive net financial income net income financial assets foreign exchange management exceeding financing costs million swiss francs groups effective tax rate reduced percentage points mainly due discontinuation amortisation goodwill january profit continuing businesses increased due combination positive developments operating financial tax lines compensated exceptional financial income results excluding aftertax income million swiss francs exceptional operating items profit continuing businesses increased billion swiss francs net income lower million swiss francs billion swiss francs duetothe inclusion billion swiss francs divested consumer health otc business associated companies result associates significant net financial income continuing businesses millions chf financing costs financial income net financial income financial income financial income showed improvement compared net income equity securities million swiss francs compared million swiss francs driven strongly performing equity markets disposal equity investments lower impairments investments interest income income debt securities doubled million swiss francs due higher holdings increases interest rates net foreign exchange losses million swiss francs compared gains million swiss francs full analysis financial income given note consolidated financial statements financing costs financing costs million swiss francs reduction mainly due retirement debt instruments bank debt lower average levels debt offset increasing interest rates floating rate debt full analysis financing costs given note consolidated financial statements finance report roche group financial review exceptional income bond conversion redemption part continuing refinancing restructuring groups debt lyons iv lyons iii notes called redemption group also redeemed part chameleon bond public tender additionally group reassessed likely future cash outflows lyons v notes concluded appropriate consider first call date july probable date cash flows net pretax gain million swiss francs arose transactions primarily groups partial disposal interest genentech conversion lyons iv notes income taxes groups effective tax rate compared rate main influence discontinuation goodwill amortisation results reduced rate percentage points underlying tax rate broadly unchanged increasing relative contribution genentech chugai groups overall results largely offset use research development tax credits areconciliation effective tax rate given note consolidated financial statements profit continuing businesses billions chf net income billions chf profit continuing businesses increase compared due positive developments operating financial tax lines offset exceptional financial income million swiss francs aftertax results excluding exceptional items profit continuing businesses increased billion swiss francs discontinued businesses results include operating results remaining otc consumer health business transferred bayer comparative results include billion swiss francs divestment gain sale initial business bayer well billion swiss francs operating results whole otc consumer health business still fully owned roche group end information discontinued businesses given note consolidated financial statements net income group net income decreased billion swiss francs return sales margin net income attributable roche shareholders lower comparative period includes billion swiss francs divested consumer health otc business exceptional financial income billion swiss francs aftertax share net income attributable minorities increased million swiss francs due continually improving profit contribution genentech chugai within million swiss francs attributable genentech minority interests million swiss francs chugai minority interests diluted eps chf chf change group continuing businesses continuing businesses exceptional items core decrease diluted eps due increase higher underlying net income offset various exceptional items included results core eps excludes exceptional items also amortisation intangible assets increased chf chf shows underlying improvements groups operating financial tax results supplementary net income eps information given includes calculations profit continuing businesses exceptional items core eps reconciles groups published ifrs results finance report roche group financial review cash flows net cash cash flows operating activities net cash income taxes billions chf billions chf condensed cash flow statement mchf mchf cash generated operations increase decrease working capital costs major legal cases paid operating cash flows operating activities income taxes income taxes paid activities operating activities investing activities financing activities net effect currency translation cash increase decrease cash full consolidated cash flow statement given consolidated financial statements operating cash flows groups business operations continued show strong cash generation billion swiss francs driven continued growth ebitda tax payments considerably higher mainly due payment tax gain disposal consumer health otc business increased payments genentech chugai overall operating cash flows increased billion swiss francs investing cash flows largest investing cash flow receipt bayer billion swiss francs proceeds divestment consumer health otc business received january investing cash flows include expenditure property plant equipment billion swiss francs particular billion swiss francs used genentech purchase oceanside biologics manufacturing facility increased net investment marketable securities billion swiss francs mainly result strong cash generation operating business large net cash inflow sales part groups portfolio marketable securities order fund repayment debt instruments financing cash flows significant financing cash flows relate dividend payments redemption debt instruments dividends paid billion swiss francs billion swiss francs cash used redemption debt instruments billion swiss francs used sumo bonds compared billion swiss francs used lyons iii notes chameleon bonds redemption conversion lyons iv notes cash impact million swiss francs debt obligation almost entirely settled delivery genentech shares genentech issued billion us dollars senior notes resulting cash inflow equivalent billion swiss francs although genentech used billion swiss francs repay finance lease obligations genentech received billion swiss francs stock option exercises period genentech repurchased shares billion swiss francs finance report roche group financial review net cash december december mchf mchf change cash cash equivalents marketable securities longterm debt shortterm debt net cash net cash increased significantly main drivers strong cash inflow operating activities billion swiss francs receipt billion swiss francs bayer payments property plant equipment stock options exercises repurchases genentech reduced net cash total billion swiss francs payment dividends reduced net cash billion swiss francs sumo redemption issue genentech senior notes repayment finance leases genentech reduce debt cash therefore overall effect net cash although shortterm debt reduced billion swiss francs balance sheet balance sheet billions chf liabilities assets net assets equity condensed balance sheet december december mchf mchf change property plant equipment goodwill intangible assets noncurrent assets cash marketable securities current assets total assets debt current noncurrent noncurrent liabilities current liabilities total liabilities total net assets capital reserves attributable roche shareholders equity attributable minority interests total equity full consolidated balance sheet given consolidated financial statements finance report roche group financial review noncurrent assets increase us dollar swiss franc december december increased longterm assets swiss franc terms since many groups production facilities intangible assets denominated us dollars purchase oceanside biologics manufacturing facility genentech increased property plant equipment billion swiss francs acquisition glycart increased goodwill intangible assets billion swiss francs following decision california supreme court february review litigation genentech city hope surety bond billion swiss francs posted genentech reclassified current assets longterm assets current assets overall current assets increased due increase liquid funds groups strong operating performance well matters described section cash flows net cash receipt billion swiss francs bayer consumer health otc business increased cash decreased current assets debt net effect issue genentech senior notes repayment finance leases genentech increased debt billion swiss francs redemption sumo bonds reduced debt billion swiss francs additionally movement us dollar exchange rates increased swiss franc carrying value groups us dollardenominated debt instruments noncurrent current liabilities provision billion swiss francs made genentech city hope litigation reclassified current liabilities noncurrent liabilities total net assetsequity significant movements net income billion swiss francs dividend payments billion swiss francs currency translation gains billion swiss francs currency translation gains mainly arose increase us dollar relative swiss franc particularly affects balance sheet values assets liabilities particular concentrations inthe us property plant equipment goodwill intangible assets debt strong financial condition group remains solidly financed equity including minority interests representing total assets total assets financed longterm roche securities price development roche securities performed significantly better swiss market peer group healthcare companies roche share price closed year swiss francs compared price swiss francs end roche nonvoting equity security genussschein closed year swiss francs compared price swiss francs end previous year comparison smi gained market capitalisation roche billion swiss francs end compared billion swiss francs end roche among leaders peer group terms total shareholder return tsr ie share price growth plus dividends yearend return roche share roche nonvoting equity security combined performance share nonvoting equity security compared weighted average return peer group peer group abbott laboratories altana amgen astrazeneca bayer becton dickinson biogen idec bristolmyers squibb elililly glaxosmithkline johnson johnson merck novartis pfizer serono sanofiaventis schering ag scheringplough takeda wyeth finance report roche group financial review total shareholder return development price tsr roche gs roche share peer group actual exchange rates roche gs roche share peer group dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments shares nonvoting equity securities issue amount billion swiss francs billion swiss francs resulting payout ratio based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given finance report information per share nonvoting equity security information per share nonvoting equity security chf chf change basic eps diluted eps group continuing businesses continuing businesses exceptional items core equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements finance report financial risks valueatrisk earningsatrisk analysis tools valueatrisk var calculations used indicate within ranges value respective assets liabilities may fluctuate certain probability certain time period holding period var measure statistical measure implicitly assuming value changes recent past indicative value changes future market shocks included calculation unless recently observed group conducts additional stress testing take possibilities consideration group uses statistically relevant observation periods applies holding periods reflect time period required change respective risk exposure deemed appropriate longer holding periods probability higher value changes increases var measure finance report roche group financial review earningsatrisk ear equivalent var methodology rather potential value changes indicates potential changes profits losses certain probability certain time period constraints limitations apply methodology var ear methodology refined holding period set trading days enhanced calculation model introduced var ear figures interest rate risks measured using historical simulation approach deltanormal approach used historical scenario representing price rate changes individual instruments specific day period past years financial instruments fully revalued using valuation models total change value earnings determined var ear calculations based confidence level holding period trading days comparative information restated group predict future market movements var ear figures given represent actual losses expected might incurred financial assets liabilities possible worst loss period stated consider effect favourable changes market rates foreign exchange risk groups exposure movements foreign currencies affecting net income financial position asexpressed swiss francs summarised following key figures comments growth continuing businesses local local currencies currencies chf chf sales operating profit exceptional items exchange rates swiss franc december average december average usd eur gbp jpy average major currencies remained stable swiss franc consequently almost difference sales growth continuing businesses operating profit growth expressed swiss francs local currencies absolute terms sensitivity group sales continuing businesses change us dollar swiss franc swiss francs approximately million swiss francs corresponding sensitivities euro yen approximately million swiss francs million swiss francs respectively group pursued strategy continuously lockin favourable developments foreign exchange rates entering derivative contracts thereby reducing exposure potential future movements foreign exchange rates foreign exchange transaction var remained low level foreign exchange risks december december mchf mchf change var monetary positions finance report roche group financial review interest rate risk interest rate risk arises movements interest rates could adverse effects groups netincome financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments appropriate group uses financial derivatives swaps manage interest rate risk genentech issued new bonds billion us dollars despite groups debt increased bybillion chf due redemption outstanding debt bank debt capitalised leases sumo bond order achieve better match term structure assets liabilities group swapped sizeable part remaining debt floating interest rates consequence exposure potential changes interest rates decreased interest rate var measuring potential change net market value interest rate sensitive assets liabilities declined interest rate var considers roches interest rate sensitive position comparatively small risks repricing refinancing contained reasonable levels however earningsatrisk ear increased mainly result liquid funds held short interest rate commitments generally higher interest rate levels allow room downward changes interest rates interest rate risks december december mchf mchf change var instruments sensitive interest rates ear instruments sensitive interest rates market risk financial assets liabilities changes market value financial assets liabilities affect net income financial position group market risk arises movements stock prices interest rates foreign exchange rates groups financial assets mostly held highly liquid fixed income money market instruments currency allocation maturity profile financial assets financial liabilities aligned equity allocation groups portfolio cash marketable securities reduced around billion swiss francs total cash marketable securities billion swiss francs december total cash marketable securities international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since since late international accounting standards board iasb published number new revised standards first became effective group implemented january fully discussed note consolidated financial statements goodwill amortisation effective january amortisation goodwill ceased although goodwill continue tested impairment change requires prospective application standard applied goodwill amortisation expenses million swiss francs continuing businesses would recorded operating results net income attributable roche shareholders would million swiss francs higher sharebased payment fair value equity compensation plans awarded employees estimated grant date recorded expense vesting period change requires retrospective application using certain transitional requirements applying transitional requirements impact previously reported operating income net income attributable roche shareholders million swiss francs million swiss francs respectively due transitional requirements indicative future impacts finance report roche group financial review recognition intangible assets revised standards intangible assets business combinations typically result intangible assets recognised acquisitions inlicensing collaborations alliances previously approximately million swiss francs previously would expensed research development expenses capitalised intangible assets standards require prospective application financial instruments group already fully applied previous ias financial instruments since additional changes implemented standards financial instruments require retrospective application significant effect equity minority interests minority interests included part groups equity separate category balance sheet increases groups equity million swiss francs applied retrospectively january presentation income statement following changes group revised presentation income statement includes full divisional split groups operating results changes made accordance requirements new revised standards order improve comparability results healthcare companies allow readers make accurate assessment sustainable earnings capacity group comparative results consolidated financial statements restated new format full details changes given note consolidated financial statements supplementary presentation materials investor update held march available investor relations section groups website wwwrochecom finance report roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit associated companies financial income financing costs profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests continuing earnings per share nonvoting equity security businesses group basic chf diluted chf finance report roche group roche group consolidated financial statements consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit associated companies financial income financing costs exceptional income bond conversion redemption profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests continuing earnings per share nonvoting equity security businesses group basic chf diluted chf disclosed note income statement restated following changes ifrs adopted effective january reconciliation previously published income statement provided note finance report roche group roche group consolidated financial statements consolidated balance sheet millions chf december december noncurrent assets property plant equipment goodwill intangible assets investments associated companies financial longterm assets longterm assets deferred income tax assets postemployment benefit assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets receivable bayer group collected january marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefits liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable minority interests total equity disclosed note balance sheet restated following changes ifrs adopted effective january reconciliation previously published balance sheet provided note finance report roche group roche group consolidated financial statements consolidated cash flow statement millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital vitamin case payments major legal cases payments made defined benefit postemployment plans utilisation restructuring provisions utilisation provisions operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets disposal products acquisitions subsidiaries associated companies divestments discontinued businesses subsidiaries associated companies interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue longterm debt instruments repayment longterm debt instruments increase decrease longterm debt transactions equity instruments increase decrease shortterm borrowings interest dividends paid exercises equitysettled equity compensation plans genentech chugai share repurchases financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december finance report roche group roche group consolidated financial statements consolidated statement recognised income expense millions chf year ended december availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations income taxes items taken directly transferred equity net income recognised directly equity net income recognised income statement total recognised income expense attributable roche shareholders minority interests total effect changes accounting policy attributable roche shareholders minority interests total finance report roche group roche group consolidated financial statements consolidated statement changes equity millions chf roche minority shareholders interests total year ended december january previously reported changes accounting policy january restated net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december year ended december january net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december finance report notes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs interpretations adopted international accounting standards board iasb comply swiss law prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors january subject approval annual general meeting shareholders february preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure ofcontingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change changes accounting policies arise application new revised standards interpretations applied retrospectively unless otherwise specified transitional requirements particular standard interpretation retrospective application requires results comparative period opening balances period restated new accounting policy always applied addition comparatives reclassified extended previously reported results take account presentational changes consolidation policy financial statements consolidated financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enterprise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled group companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group inter company balances transactions resulting unrealised income eliminated full investments associated companies accounted equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights potential voting rights company balances transactions associated companies result unrealised income eliminated extent groups interest associated company interests joint ventures reported using linebyline proportionate consolidation method segment reporting groups primary format segment reporting business segments secondary format geographical segments risks returns groups operations primarily determined different products group produces rather geographical location groups operations reflected groups management organisational structure internal financial reporting systems finance report roche group notes roche group consolidated financial statements determination groups business geographic segments based organisation units information reported groups management group two divisions pharmaceuticals diagnostics within pharmaceuticals division three subdivisions roche pharmaceuticals genentech chugai three subdivisions separate management reporting structures within pharmaceuticals division considered separately reportable business segments vitamins fine chemicals business consumer health otc business previously separately reportable business segments divested presented discontinued businesses certain headquarter activities reported corporate consist corporate headquarters including corporate executive committee corporate communications corporate human resources corporate finance including treasury taxes pension fund management corporate legal safety environmental services groups geographical segments determined geographical location similarity economic environments transfer prices business segments set arms length basis divisional assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories segment assets liabilities consist assets liabilities reasonably attributed reported business segments include pension assetsliabilities provisions non segment assets liabilities mainly include current deferred income tax balances financial assets liabilities principally cash marketable securities investments debt capital expenditure comprises additions goodwill intangible assets property plant equipment including arising acquisitions foreign currency translation group companies use local currency functional currency certain group companies use currencies namely us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity deferred equity upon consolidation assets liabilities group companies using functional currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity disposal foreign entity identified cumulative currency translation differences within equity relating foreign entity recognised income part gain loss divestment revenues cost sales sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates excluding sales value added taxes revenues sale products recognised upon transfer customer significant risks rewards usually upon shipment trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid united states similar rebates countries also deducted sales recorded accrued liabilities provisions estimates based analyses existing contractual legislativelymandated obligations historical trends groups experience revenues recorded earned services performed necessary single transactions split separately identifiable components reflect substance transaction conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales includes corresponding direct production costs related production overhead goods sold services rendered startup costs validation achievement normal production capacity expensed incurred finance report roche group notes roche group consolidated financial statements royalty income expenses royalty income expenses recognised accrual basis royalty expenses directly linked goods sold included cost sales royalty expenses included general administration research development addition internal research development activities group also party inlicensing similar arrangements alliance partners furthermore group may acquire inprocess research development assets either business combinations purchases specific assets internal research costs charged income incurred internal development costs capitalised intangible assets identifiable asset generate expected future economic benefits cost asset measured reliably group currently internal development costs qualify capitalisation intangible assets internal development costs charged income incurred since criteria recognition asset met inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases capitalised intangible assets described available use intangible assets amortised straightline basis period expected benefit reviewed impairment balance sheet date licensing milestone upfront receipts payments certain group companies receive third parties upfront milestone similar nonrefundable payments relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements non refundable upfront payments licence fees initially reported deferred income recognised revenue income earned period development collaboration manufacturing obligation payments made group companies third parties associated companies items capitalised intangible assets receipts payments consolidated subsidiaries genentech chugai roche group subsidiaries eliminated consolidation taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable intention remit earnings deferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying amounts financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates discontinued businesses noncurrent assets held sale discontinued business component groups business represents separate major line business geographical area operations subsidiary acquired exclusively view resale reclassification discontinued business occurs upon disposal operation meets criteria classified held sale earlier finance report roche group notes roche group consolidated financial statements disposal group group assets disposed group single transaction together liabilities directly associated assets transferred transaction assets liabilities disposal group reclassified heldforsale value recovered principally sale rather continuing use disposal group must available sale current condition sale must highly probable immediately classification heldforsale measurement assets liabilities disposal groupis brought uptodate accordance applicable accounting policies initial reclassification heldforsale disposal groups recognised lower carrying amount fair value less costs sell impairment losses initial classification heldforsale included income statement employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned liabilities longterm employee benefits discounted take account time value money material pensions postemployment benefits employees covered defined benefit defined contribution postemployment plans sponsored group companies accounting reporting defined benefit plans based recent actuarial valuations defined benefit obligations service costs calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned differences assumptions actual experiences effects changes actuarial assumptions allocated estimated average remaining working lives employees differences exceed defined corridor past service costs allocated average period benefits become vested expenses defined benefit plans charged theappropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate business segment pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited net total unrecognised actuarial losses past service costs present value future refunds plans reductions future contributions plans groups contributions defined contribution plans charged income statement year relate equity compensation plans certain employees group participate equity compensation plans including separate plans genentech chugai fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded subsequent cash flows exercises vested awards recorded increase equity cashsettled plans liability recorded measured fair value balance sheet date movements fair value recorded appropriate income statement heading within operating results subsequent cash flows exercises vested awards recorded reduction liability finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment initially recorded cost purchase construction depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate items estimated useful life assets regularly reviewed necessary future depreciation charge accelerated repairs maintenance costs expensed incurred borrowing costs capitalised leases leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt assets acquired finance leases depreciated accordance groups policy property plant equipment interest element lease payment charged income lease term based effective interest rate method leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease group lessor assets subject finance leases reported receivables amount equal net investment lease assets subject operating leases reported within property plant equipment lease income finance leases recognised term lease based effective interest rate method lease income operating leases recognised lease term straightline basis business combinations goodwill business combinations accounted using purchase method accounting cost acquisition consideration given exchange control identifiable assets liabilities contingent liabilities ofthe acquired company consideration includes cash paid plus fair value date exchange assets given liabilities incurred assumed equity instruments issued group cost acquisition also includes directly attributable costs acquired net assets identifiable assets liabilities contingent liabilities initially recognised fair value group acquire ownership acquired company minority interest recorded minoritys proportion fair value acquired net assets goodwill recorded surplus cost acquisition groups interest fair value acquired net assets goodwill fair value adjustments recorded assets liabilities acquired company recorded local currency company goodwill amortised assessed possible impairment balance sheet date additionally tested annually impairment goodwill may also arise upon investments associated companies surplus cost investment groups share fair value net identifiable assets goodwill recorded within investments associated companies finance report roche group notes roche group consolidated financial statements intangible assets patents licences trademarks intangible assets initially recorded cost assets acquired business combination fair value allocated acquisition accounting acquired business combination initial fair value cost intangible assets amortised useful lives straightline basis beginning point available use estimated useful life lower legal duration economic useful life estimated useful life intangible assets regularly reviewed amortisation impairment intangible assets presented separately income statement due materiality amounts order fairly present groups results impairment property plant equipment intangible assets evidence asset may impaired recoverable amount asset calculated animpairment assessment carried recoverable amount asset higher fair value less costs sell value use less carrying amount carrying amount reduced recoverable value reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy impairment goodwill impairment assessment goodwill carried annually goodwill allocated cashgenerating units groups business segments recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying amount impairment carrying amount recorded methodology used impairment testing cashgenerating units described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities borrowing costs included cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts allowance recorded difference carrying amount recoverable amount objective evidence group able collect amounts due longterm accounts receivable discounted take account time value money material provisions sales returns sales chargebacks reported provisions accrued liabilities respectively cash cash equivalents cash cash equivalents includes cash hand time call current balances banks similar institutions balances reported cash readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used cash flow statement provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign currency effects arising translation functional currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable finance report roche group notes roche group consolidated financial statements fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices use established estimation techniques option pricing models estimated discounted values cash flows fair values financial assets liabilities balance sheet date approximately line reported carrying values unless specifically mentioned notes consolidated financial statements financial assets financial assets principally investments including marketable securities classified either fairvalue throughprofitorloss availableforsale heldtomaturity loans receivables fairvaluethrough profitorloss financial assets either classified heldfortrading designated upon initial recognition heldfortrading financial assets acquired principally generate profit shortterm fluctuations price financial assets designated fairvaluethroughprofitorloss results relevant information eliminating measurement recognition inconsistency heldtomaturity financial assets securities fixed maturity group intent ability hold maturity loans receivables loans longterm financial assets created group acquired issuer primary market nonderivative financial assets fixed determinable payments financial assets considered availableforsale financial assets initially recorded fair value including transaction costs except assets designated fairvaluethroughprofitorloss exclude transaction costs purchases sales recognised settlement date fairvaluethroughprofitorloss financial assets subsequently carried fair value changes fair value recorded financial income period arise heldtomaturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded equity availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised equity included financial income current period loans receivables subsequently carried amortised cost financial assets assessed possible impairment balance sheet date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale financial assets market value original cost net previous impairment considered impaired availablefor sale financial assets market value original cost net previous impairment sustained sixmonth period considered impaired decreases market price less original cost net previous impairment also less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity objective evidence impairment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried equity difference original cost net previous impairment fair value financial assets derecognised contractual rights cash flows assets expire group sells otherwise disposes contractual rights cash flows including situations group retains contractual rights assumes contractual obligation pay cash flows third party derivatives derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments see changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract host contract carried amortised cost finance report roche group notes roche group consolidated financial statements hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing future cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change infairvalue effective hedge included equity remaining ineffective portion reported financial income hedging relationship hedge firm commitment highly probable forecasted transaction results recognition nonfinancial asset liability cumulative changes fair value hedging instrument recorded equity included initial carrying value asset liability date recognition qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income hedging instrument derivative equity cases entity disposed cumulative changes fair value hedging instrument recorded equity reclassified income debt instruments debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost using effective interest method discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method certain debt instruments may designated fairvaluethroughprofitorloss results relevant information eliminates significantly reduces measurement recognition inconsistencies would previously occurred instruments subject qualifying fair value hedges debt instruments reported fair value based quoted prices active market movements fair value reported within financial income debt instruments designated fairvaluethroughprofitorloss disclosed note bifurcation carried upon issue convertible debt instruments initial carrying value liability element calculated using market interest rate equivalent nonconvertible instrument remainder net proceeds allocated equity conversion option reported equity deferred income tax liabilities liability element subsequently reported amortised cost fairvaluethrough profitandloss designated finance report roche group notes roche group consolidated financial statements equity instruments groups holdings equity instruments recorded deduction equity original cost acquisition consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet obligations may arise respect certain groups debt instruments management judgements made applying accounting policies application groups accounting policies may require management make judgements apart involving estimates significant effect amounts recognised consolidated financial statements management judgement particularly required assessing substance transactions complicated structure legal form include limited following areas revenue recognition nature groups business many sales transactions simple structure sales agreements may consist multiple components occurring different times group also party various outlicensing agreements involve upfront milestone payments may occur several years agreements may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement leases group party leasing arrangements lessor lessee treatment leasing transactions financial statements mainly determined whether lease considered operating lease finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred key assumptions sources estimation uncertainty preparation consolidated financial statements conformity ifrs requires management make estimates assumptions affect application policies reported amounts assets liabilities income expenses related disclosures estimates underlying assumptions based historical experience various factors believed reasonable circumstances results form basis making judgements carrying values assets liabilities readily apparent sources actual results may differ estimates estimates underlying assumptions reviewed ongoing basis changes accounting estimates may necessary changes circumstances estimate based result new information experience changes recognised period estimate revised key assumptions future key sources estimation uncertainty significant risk causing material adjustment carrying value assets liabilities within next twelve months described finance report roche group notes roche group consolidated financial statements revenue recognition group accruals provisions expected sales returns chargebacks rebates including medicaid united states similar rebates countries december total million swiss francs estimates based analyses existing contractual legislativelymandated obligations historical trends groups experience management believes total accruals provisions items adequate based upon currently available information deductions based management estimates may subject change better information becomes available changes arise could impact accruals provisions recognised balance sheet future periods consequently level sales recognised income statement future periods property plant equipment intangible assets including goodwill group property plant equipment carrying value million swiss francs disclosed note goodwill carrying value million swiss francs see note intangible assets carrying value million swiss francs see note assets reviewed annually impairment described assess impairment exists estimates made future cash flows expected result use asset eventual disposal actual outcomes could vary significantly estimates discounted future cash flows factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment pensions postemployment benefits many groups employees participate post employment defined benefit plans calculations recognised assets liabilities plans based upon statistical actuarial calculations particular present value defined benefit obligation impacted assumptions discount rates used arrive present value future pension liabilities assumptions future increases salaries benefits furthermore groups independent actuaries use statistically based assumptions covering areas future withdrawals participants plan estimates life expectancy december present value groups defined benefit obligation million swiss francs funded plans million swiss francs unfunded plans see note actuarial assumptions used may differ materially actual results due changes market economic conditions higher lower withdrawal rates longer shorter life spans participants changes factors assessed differences could impact assets liabilities recognised balance sheet future periods legal provisions group companies party various legal proceedings significant matters described notes legal provisions december total million swiss francs asdisclosed note additional claims could made might covered existing provisions insurance assurance increase scope matters future lawsuits claims proceedings investigations material changes arise could impact provisions recognised balance sheet future periods environmental provisions group provisions environmental remediation costs december total million swiss francs disclosed note material components environmental provisions consist costs fully clean refurbish contaminated sites treat contain contamination certain sites future remediation expenses affected number uncertainties include limited detection previously unknown contaminated sites method extent remediation percentage waste material attributable group remediation sites relative attributable parties financial capabilities potentially responsible parties management believes total provisions environmental matters adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued effect resolution environmental matters results operations predicted due uncertainty concerning amount timing future expenditures results future operations changes arise could impact provisions recognised balance sheet future periods finance report roche group notes roche group consolidated financial statements income taxes december net liability current income taxes million swiss francs net liability deferred income taxes million swiss francs disclosed note significant estimates required determining current deferred assets liabilities income taxes estimates based interpretations existing tax laws regulations management believes estimates reasonable recognised liabilities income taxrelated uncertainties adequate various internal external factors may favourable unfavourable effects income tax assets liabilities factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations future levels rd spending changes overall levels pretax earnings changes arise could impact assets liabilities recognised balance sheet future periods changes accounting policies late international accounting standards board iasb published revised version ias financial instruments disclosure presentation revised version ias financial instruments recognition measurement improvements international accounting standards makes changes existing standards first quarter iasb published ifrs sharebased payment ifrs business combinations ifrs insurance contracts ifrs noncurrent assets held sale discontinued operations revised versions ias impairment assets ias intangible assets amendments ias mid iasb issued revision ias regarding fair value option group adopted effective january description changes effect consolidated financial statements given ias accounting policies changes accounting estimates errors amongst matters revised standard requires changes accounting policies arise application new revised standards interpretations applied retrospectively unless otherwise specified transitional requirements particular standard interpretation previously group applied changes prospectively unless otherwise specified transitional requirements retrospective application requires results comparative period opening balances period restated new accounting policy always applied prospective application requires new accounting policy applied results current period comparative period restated ifrs sharebased payment amongst matters new standard requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading groups previous policy expenses recorded equitysettled equity compensation plans expenses cashsettled equity compensation plans recorded based intrinsic value outstanding obligation part operating expenses standard also requires retrospective application within certain transitional requirements transitional requirements require companies apply new standard retrospective effect awards made november yet vested december additionally cashsettled awards exercised december applying transitional requirements pretax expense million swiss francs recorded million swiss francs restated results due impact transitional requirements amounts indicative future expenses plans expenses cashsettled plans totalling million swiss francs reclassified operating expenses impact application ifrs restated operating results millions chf retrospective previously reported impact application operating restated ifrs expenses results cost sales marketing distribution research development general administration total operating expense finance report roche group notes roche group consolidated financial statements addition amounts expenses totalling million swiss francs roche connect roche performance share plan already included operating results originally published therefore need restated new standard also affects groups effective tax rate deferred tax recorded based expected tax benefits arising vested awards united states many tax jurisdictions current equity price used input calculation impact income statement income tax benefit capped reference ifrs pretax expense excess recognised directly equity information groups equity compensation plans given note ifrs business combinations amongst matters new standard requires amortisation goodwill cease date implementation goodwill continue tested impairment standard requires prospective application standard applied goodwill amortisation expenses million swiss francs continuing businesses million swiss francs discontinued businesses would recorded additional impairment would necessary addition together ias revised intangible assets standard typically result intangible assets recognised acquisitions previously consequently less goodwill arise new standard also affects groups effective tax rate tax benefit recorded respect goodwill amortisation based groups results groups effective tax rate expected decrease two three percentage points ias revised intangible assets amongst matters revised standard typically result intangible assets recognised inlicensing arrangements similar research development alliances previously expenditure would recorded research development expenses revised standard requires prospective application ias revised ias revised financial instruments since group already fully applied previous ias ias financial instruments revised standards significant effect groups results financial position amongst matters revised standards require significant orprolonged decline fair value availableforsale financial assets considered objective evidence impairment groups previous accounting policy decline fair value availableforsale financial assets considered objective evidence impairment decline significant prolonged consequently revised standards typically result impairment charges recognised available forsale financial assets earlier stage previous accounting policy additionally group adopted revision ias regarding fair value option three groups debt instruments asspecified note designated fairvaluethroughprofitorloss previously subject qualifying fair value hedges designation fairvaluethroughprofitorloss results relevant information eliminates significantly reduces measurement recognition inconsistencies revised standards require retrospective application additionally results restatement equity conversion elements certain groups convertible debt instruments result equity january reduced million swiss francs additional pretax income million swiss francs recorded restated results ias revised presentation financial statements amongst matters revised standard requires presentation results discontinued businesses single amount face income statement additionally revised standard requires minority interests included part groups equity separate category balance sheet addition revised standard permits separate presentation statement recognised income expense statement transactions equity holders acting capacity equity holders finance report roche group notes roche group consolidated financial statements presentation income statement new revised standards result significant changes format content income statement addition group made certain presentational changes improve comparability results healthcare companies allow readers make accurate assessment sustainable earnings capacity group changes applied retrospectively listed royalties operating income shown separate line sales cost sales includes royalty expenses directly linked goods sold million swiss francs million swiss francs operating expenses removed income statement administration expanded general administration additionally include operating expenses royalty expenses included cost sales financial income financing costs disclosed separately face income statement capital taxes reported part general administration instead financial income previously million swiss francs million swiss francs included corporate business segment restated income statement year ended december millions chf originally discontinued ias group published businesses ifrs ias changes restated sales operating items operating profit financial nonoperating items profit taxes income taxes profit continuing businesses na profit discontinued businesses na net income attributable roche shareholders minority interests earnings per share nonvoting equity security diluted group chf presentation balance sheet balance sheet december restated following changes ifrs adopted effective january result implementation ifrs net assets december million swiss francs higher consists inventories million swiss francs asset deferred tax assets million swiss francs asset liabilities cashsettled equity compensation plans million swiss francs liability result implementation ias revised ias revised net assets december million swiss francs lower consists longterm debt million swiss francs liability deferred tax assets million swiss francs asset addition provisions sales returns sales chargebacks classified provisions accrued liabilities respectively previously reported within accounts receivable reclassification made appropriately present balances december balance sheet total million swiss francs reclassified accounts receivable provisionscurrent million swiss francs accrued liabilities million swiss francs impact net income equity reclassification finance report roche group notes roche group consolidated financial statements restated balance sheet december millions chf originally ias ias group published revised ifrs ias changes restated noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities total net assets minority interests equity presentation changes equity new revised standards result significant changes format content changes equity particular ias revised permits separate presentation statement recognised income expense statement transactions equity holders acting capacity equity holders addition group made certain presentational changes order fairly present groups financial position changes applied retrospectively listed result implementation ias revised ifrs net accounting effect genentech chugai stock repurchases stock options recorded equity allocated retained earnings minority interests based relevant ownership percentages previously entries recorded minority interests standards require retrospective application accordingly million swiss francs reclassified minority interests retained earnings january equity element arising issue convertible debt shown within retained earnings rather separate reserve accordingly million swiss francs reclassified retained earnings january restated equity january millions chf originally ias ias group published revised ifrs ias changes restated share capital equity instruments retained earnings fair value reserve hedging reserve translation reserve equity conversion reserve equity attributable roche shareholders minority interests total equity total impact changes accounting policies equity million swiss francs negative million swiss francs attributable roche shareholders million swiss francs attributable minority interests finance report roche group notes roche group consolidated financial statements group currently assessing potential impacts new revised standards effective january effective january group apply ias revised employee benefits amongst matters revised standard allows actuarial gains losses defined benefit plans recorded directly equity case adjustments arising limits recognition assets defined benefit plans also recorded directly equity revised standard requires retrospective application group estimates restated results profit tax approximately million swiss francs higher net income approximately million swiss francs higher equity december approximately billion swiss francs lower group expect new revised standards interpretations significant effect groups results financial position although expand disclosures certain areas notably ifrs financial instruments disclosures group implement financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties groups subsidiaries genentech chugai treasury operations operational independence whilst working within financial risk management framework consistent rest group information financial risks available annual reports genentech chugai financial risk management within group governed policies guidelines approved senior management policies guidelines cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policies guidelines also cover areas cash management investment excess funds raising short longterm debt compliance policies guidelines managed segregated functions within group objective financial risk management contain deemed appropriate exposures various types financial risks mentioned order limit negative impact groups results financial position group actively measures monitors manages financial risk exposures various functions pursuant segregation duties principles accordance financial risk policies group manages market risk exposures use financial instruments derivatives deemed appropriate groups policy practice enter derivative transactions trading speculative purposes purposes unrelated underlying business foreign exchange risk group operates across world exposed movements foreign currencies affecting net income financial position expressed swiss francs group actively monitors currency exposures appropriate enters transactions aim preserving value assets commitments anticipated transactions group uses forward contracts foreign exchange options crosscurrency swaps hedge certain committed anticipated foreign exchange flows financing transactions transaction exposure arises amount local currency paid received transactions denominated foreign currencies may vary due changes exchange rates many group companies revenues operating expenses primarily local currency similarly transaction exposure arises net balances monetary assets held foreign currencies local level group companies manage exposure necessary means financial instruments options forward contracts addition group treasury monitors total worldwide exposure monthly basis finance report roche group notes roche group consolidated financial statements translation exposure arises consolidation foreign currency denominated financial statements groups foreign subsidiaries effect groups consolidated equity shown currency translation movement group partially hedges net investments foreign currencies taking foreign currency loans issuing foreign currency denominated debt instruments major translation exposures monitored regularly significant part groups cash outflows research development production administration denominated swiss francs much smaller proportion groups cash inflows swiss franc denominated result increase value swiss franc relative currencies adverse impact consolidated net income similarly relative decrease value swiss franc favourable effect results reported swiss francs interest rate risk interest rate risk arises movements interest rates could effects groups net income financial position changes interest rates may cause variations interest income expenses resulting interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments described following section market risk financial assets interest rates groups major debt instruments fixed described note group uses interest rate derivatives manage interest rate risk market risk financial assets changes market value certain financial assets derivative instruments affect net income financial position group financial longterm assets held strategic purposes marketable securities held fund management purposes risk loss value managed reviews prior investing continuous monitoring performance investments changes risk profile investments equities bonds debentures fixed income instruments entered basis guidelines regard liquidity credit rating credit risk credit risk arises possibility counterparty transaction may unable unwilling meet obligations causing financial loss group trade receivables subject policy active risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures significant concentrations within trade receivables counterparty credit risk due groups large number customers wide geographical spread credit exposures critical countries group obtained credit insurance country risk limits exposures continuously monitored exposure financial assets credit risk controlled setting policy limiting credit exposure highquality counterparties regular reviews credit ratings setting defined limits individual counterparty appropriate reduce exposure netting agreements isda international swaps derivatives association master agreement signed respective counterparties maximum exposure credit risk resulting financial activities without considering netting agreements equal carrying amount financial assets plus positive fair value derivative instruments credit exposure diversified amongst different counterparties liquidity risk group companies need sufficient availability cash meet obligations individual companies generally responsible cash management including shortterm investment cash surpluses raising loans cover cash deficits subject guidance group certain cases approval group level group maintains sufficient reserves cash readily realisable marketable securities meet liquidity requirements times addition strong international creditworthiness group gives ability efficiently use international capital markets financing purposes syndicated credit facility billion euros established term seven years facility utilised finance report roche group notes roche group consolidated financial statements segment information divisional information millions chf roche pharmaceuticals genentech chugai segment revenues segment revenuesdivisional sales less interdivisional sales divisional sales third parties segment results operating profit exceptional items amortisation goodwill major legal cases changes group organisation segment resultsoperating profit segment assets liabilities divisional assets segment assets segment assets nonsegment assets total assets divisional liabilities segment liabilities segment liabilities nonsegment liabilities total liabilities segmental expense information research development costs equity compensation plan expenses restructuring expenses capital expenditure acquisitions additions property plant equipment additions intangible assets total capital expenditure segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets income associated companies investments associated companies finance report roche group notes roche group consolidated financial statements pharmaceuticals diagnostics division division corporate group finance report roche group notes roche group consolidated financial statements information geographical segmentin millions chf sales third parties destination segment assets capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total genentech effective september group acquired majority interest approximately genentech inc biotechnology company united states june group exercised option acquire remaining shares genentech june point genentech became owned subsidiary group july october march group completed public offerings genentechs common stock reduced groups majority interest genentech issues additional shares common stock connection equity compensation plans also may issue additional shares purposes affects groups percentage ownership interest affiliation agreement group genentech provides amongst things genentech establish stock repurchase programme maintain groups percentage ownership interest genentech finance report roche group notes roche group consolidated financial statements groups ownership genentech decreased due conversion redemption lyons iv us dollar exchangeable notes described note changes groups ownership also occurred due stock repurchases genentech exercise stock options genentech employees effective april genentech implemented twoforone share split genentechs common stock form stock dividend impact either groups percentage ownership genentech groups consolidated results december groups interest genentech common stock genentech publicly traded listed new york stock exchange symbol dna genentech prepares financial statements conformity accounting principles generally accepted united states us gaap filed quarterly basis us securities exchange commission sec differences ifrs us gaap due certain consolidation entries differences requirements international financial reporting standards ifrs us gaap differences genentechs standalone financial results us gaap basis financial results genentech consolidated roche group accordance withifrs reconciliation genentech results usd chf usd chf millions millions millions millions operating margin us gaap basis redemption costs special litigation items operating margin nonus gaap basis add deduct differences consolidation entries add back redemption costs expenses equity compensation plans differences consolidation entries operating profit exceptional items ifrs basis add deduct exceptional items amortisation goodwill segment resultoperating profit ifrs basis add deduct nonoperating items ifrs basis financial income financing costs income taxes net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis translated usd chf usd chf effective january group adopted ifrs sharebased payment ifrs financial statements amongst matters new standard requires fair value equity compensation plans awarded employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading standard also requires retrospective application within certain transitional requirements applying transitional requirements pretax expense million us dollars million swiss francs relating plans genentech recorded restated million us dollars million swiss francs due impact transitional requirements amounts indicative future expenses plans finance report roche group notes roche group consolidated financial statements genentechs us gaap financial statements currently expenses recorded plans genentech adopt us statement financial accounting standards r sharebased payment fas r effective january amongst matters require companies reporting us gaap recognise compensation expenses plans due different dates first application measurement requirements transitional arrangements fas r ifrs expenses recorded genentech us gaap financial statements equity compensation plans expenses recorded roche group ifrs financial statements plans differences ifrs us gaap relatively minor impact genentech stock repurchases june genentechs board directors authorised extension current stock repurchase programme repurchase billion us dollars genentechs common stock june initially december genentechs board directors authorised stock repurchase programme repurchase billion us dollars genentechs common stock extended additional billion us dollars september genentech repurchased common stock worth million us dollars million swiss francs million us dollars million swiss francs oceanside biologics manufacturing facility june genentech completed purchase oceanside biologics manufacturing facility sandiego california biogen idec purchase cost including closing costs million swiss francs genentech senior notes july genentech completed private placement billion us dollars aggregate principal amount year year year senior notes placement consists million us dollars senior notes due billion us dollars senior notes due million us dollars senior notes due genentech used intends use proceeds reduction repayment certain lease arrangements funding future capital expenditure including upgrade startup validation costs oceanside general corporate purposes details given note genentech leases third quarter genentech paid million us dollars buy finance lease obligations respect manufacturing facility vacaville california certain buildings south san francisco site carrying value obligations december million us dollars million swiss francs december genentech entered master lease agreement slough ssf llc lease property adjacent genentechs south san francisco site lease take place two phases phase building leases begin phase building leases may begin early ifrs leases accounted finance leases genentech expects completion project total spending owned improvements leased assets excess million us dollars total lease payments contemplated master lease agreement currently estimated million us dollars matters details genentech legal cases given note details genentechs equity compensation plans given note chugai effective october roche group chugai completed alliance create leading research driven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai finance report roche group notes roche group consolidated financial statements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements conformity accounting principles generally accepted japan jgaap filed quarterly basis tokyo stock exchange differences ifrs jgaap due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone financial results jgaap basis financial results chugai consolidated roche group accordance ifrs acquiring roche interest chugai treated acquisition ifrs jgaap alliance treated merger chugai nippon roche therefore jgaap results chugai include goodwill fair value adjustments recorded roches results quantified table moreover acquisition accounting includes roches fair value adjustments therefore impact net income needs added back minority interest calculations roches ifrs results roches ifrs results depreciation property plant equipment calculated using straightline method chugais jgaap results reducing balance method used additionally certain income expenses notably restructuring costs required jgaap reported extraordinary items chugais jgaap results extraordinary items reported operating profit line roches ifrs results items normally included part operating profit treated extraordinary exceptional items restructuring costs million swiss francs million swiss francs differences ifrs jgaap relatively minor impact reconciliation chugai results millions chf chugai operating profit exceptional items acquisition accounting impacts ifrs basis depreciation property plant equipment amortisation acquisitionrelated intangible assets chugai operating profit exceptional items ifrs basis add deduct exceptional items amortisation goodwill chugai segment resultoperating profit ifrs basis add deduct corporate chugai otc nonoperating items ifrs basis gain settlement defined benefit plans financial income financing costs chugai otc income taxes net income ifrs basis minority interest calculation add back acquisition accounting impact net income net income excluding acquisition accounting minority interest percentage average year income applicable minority interest ifrs basis translated jpy chf jpy chf dividends dividends distributed third parties holding chugai shares totalled million japanese yen million swiss francs million japanese yen million swiss francs recorded minority interests see note dividends paid chugai roche eliminated consolidation intercompany items finance report roche group notes roche group consolidated financial statements restructuring production facilities february chugai announced restructuring production facilities five existing plants integrated two facilities within next five six years part restructuring plant kagamiishi sold first half total restructuring costs including loss disposal kagamiishi plant million swiss francs shown extraordinary loss chugais jgaap financial statements pensions postemployment benefits second half chugai returned part employees pension fund japanese government result settlement gain million swiss francs accordance groups management organisational structure reported general administration expenses within corporate business segment shown extraordinary gain chugais jgaap financial statements chugai otc effective december chugai sold otc business lion corporation pretax gain disposal million swiss francs recorded results chugais otc business included profit discontinued businesses see also note early retirement programme may chugai announced early retirement programme retirement date september end application period august total employees applied programme restructuring costs billion japanese yen million swiss francs recorded programme shown extraordinary loss chugais jgaap financial statements share repurchases chugai repurchased common shares total consideration billion japanese yen million swiss francs result groups ownership chugai increased share repurchases chugai convertible bonds details series chugai pharmaceutical unsecured convertible bonds including conversions year given note royalties operating income royalties operating income millions chf royalty income income outlicensing agreements gains disposal products total royalties operating income royalty income royalty income pharmaceuticals division million swiss francs million swiss francs diagnostics division million swiss francs million swiss francs income outlicensing agreements certain group companies receive third parties upfront milestone similar nonrefundable payments relating sale licensing products technology revenue associated performance milestones recognised based achievement milestones defined respective agreements revenue nonrefundable upfront payments licence fees initially reported deferred income recognised income earned period development collaboration manufacturing obligation finance report roche group notes roche group consolidated financial statements gains disposal products part continuous realignment product portfolio group periodically disposes product lines longer considered core products priorities within product development portfolio proceeds reinvested groups inlicensing arrangements research development alliances collaborations february group announced sale exclusive us rights soriatane connetics corporation cash received million swiss francs august group agreed license sell certain patent rights patent portfolio third party cash received million swiss francs disposals products concerned book value gain disposal cash proceeds disposals reported within segment results roche pharmaceuticals business segment major legal cases income expenses major legal cases millions chf roche pharmaceuticals legal cases genentech legal cases diagnostics legal cases total income expense roche pharmaceuticals legal cases roche diagnostics gmbh rdg smithkline beecham cork ltd sb party arbitration concerning rdgs termination carvedilol license agreement amended relating licensing comarketing carvedilol rdg submitted two claims damages two arbitration tribunals zurich sb submitted counterclaim asserting invalidity rdgs termination claiming damages based development current arbitration settlement negotiations group increased existing provisions million swiss francs additional expense recorded part roche pharmaceuticals segment result disclosed separately income statement due materiality amount order fairly present groups results total amount provisions recorded rdg disclosed may seriously prejudice rdgs position matter genentech legal cases june genentech announced los angeles county superior court jury voted award city hope medical center city hope approximately million us dollars compensatory damages based finding breach agreement genentech city hope june jury voted award city hope million us dollars punitive damages case september genentech filed notice appeal jury verdict damages awards california court appeal october court appeal affirmed verdict damages awards respects also october genentech announced would seek review california supreme court discretion cases review november genentech filed petition review california supreme court february california supreme court granted petition full provision classified longterm recorded damages awards appeals process interest accrues total amount damages simple annual rate following judgement interest million swiss francs million swiss francs recorded time cost provisions within financing costs october genentech entered arrangement thirdparty insurance companies post surety bond million us dollars connection judgement part arrangement genentech pledged million us dollars cash investments secure bond thiswas increased million us dollars million us dollars million us dollars million us dollars million swiss francs amount reported restricted cash within financial longterm assets see note consolidated financial statements approved prior february decision california supreme court referred provisions restricted cash respect litigation classified current following february decision reclassified financial statements current noncurrent resolution matter expected take one year comparative information restated finance report roche group notes roche group consolidated financial statements august united states patent trademark office declared interference chiron us patent patent application exclusively licensed genentech university pennsylvania relating antiher antibodies declaring interference us patent trademark office determined substantial question whether inventors chiron patent first invent technology involved entitled patent subsequently us patent trademark office redeclared interference include addition abovereferenced chiron patent university patent application number patents patent applications owned either chiron genentech including chiron patent also issue second patent infringement lawsuit filed march genentech chiron november us patent trademark office issued rulings several preliminary motions rulings terminated interferences involving patent application referenced genentech licensed university redeclared interferences genentech chiron patents patent applications made several determinations could affect validity genentech chiron patents patent applications involved remaining interferences january genentech filed notice appeal us court appeals federal circuit june genentech chiron agreed settlement interference proceedings october genentech received subpoena united states department justice requesting documents related promotion rituxan prescription product approved treatment relapsed refractory lowgrade follicular cdpositive bcell nonhodgkins lymphoma genentech cooperating associated investigation genentech advised civil criminal nature potential outcome matter determined time may request filed third party reexamination us patent cabilly patent coowned genentech city hope july us patent trademark office ordered reexamination patent september us patent trademark office issued aninitial nonfinaloffice action rejecting claims patent action routine expected next step reexamination procedure reexamination process ongoing final outcome matter determined time second reexamination request patent filed december another third party us patent trademark office yet taken action respect additional request cabilly patent expires relates methods used genentech others make certain antibodies antibody fragments well cells dna used methods genentech licensed cabilly patent companies derives significant royalties licences claims cabilly patent remain valid enforceable throughout reexamination process july former genentech employee whose employment ended april filed nonpublic qui tam complaint seal united states district court district maine genentech biogen idec alleging violations false claims act retaliatory discharge employment december usfederal government filed notice election decline intervention lawsuit complaint subsequently unsealed genentech served january genentech evaluating complaint thepotential outcome determined time genentechs annual report quarterly sec filings contain detailed disclosures litigation matters required us gaap include details matters well including information litigation currently significant matters referred diagnostics legal cases provisions certain litigation arbitration matters diagnostics division increased million swiss francs provisions recorded based current litigation settlement negotiations recent settlement agreements additional expense disclosed separately income statement duetothe materiality amount order fairly present groups results payments totalled million swiss francs finance report roche group notes roche group consolidated financial statements october applera corporation applera filed suit group superior court california filed notice arbitration american arbitration association superior court lawsuit arbitration demand made claims concerning interpretation enforcement contracts group applera commercialisation polymerase chain reaction pcr technology claims sought termination certain contracts declarations regarding rights obligations contracts monetary damages relief unspecified amount alleged breaches various agreements parties december group filed response arbitration proceeding thesame day group also responded appleras complaint superior court proceeding petitioning court compel arbitration claims alleged applera stay lawsuit pending completion arbitration october court appeal state california ruled petition compel arbitration granted remanded case superior court directions grant petition may group announced settlement agreement reached applera regard outstanding litigation arbitration related contractual relationships involving rights commercialisation polymerase chain reaction pcr technology group filed suit promega corporation promega alleging patent infringement breach licence agreement relating polymerase chain reaction pcr technology may us district court northern district california decided one patents concerned unenforceable rejected breach licence claim november group notified promega filed nonpublic qui tam action group us district court eastern district west virginia march complaint filed false claims act alleges us federal government overcharged purchase pcr enzyme products july us federal government notified court decision intervene promegas complaint november court ordered complaint unsealed group filed motion dismiss complaint august court dismissed complaint prejudice september group announced settlement agreement reached promega regard outstanding litigation related polymerase chain reaction pcr technology changes group organisation listing major group subsidiaries associated companies included note discontinued businesses discussed note gains losses changes group organisation millions chf consumer health otc business gain loss disposal attributable roche pharmaceuticals business total net cash flows changes group organisation millions chf acquisitions glycart igen acquisitions total cash flows acquisitions subsidiaries associated companies divestments consumer health otc business divestments total cash flows divestments discontinued businesses subsidiaries associated companies amounts net cash balances acquireddivested companybusiness finance report roche group notes roche group consolidated financial statements acquisitions glycart effective july group acquired controlling interest glycart biotechnology ltd hereafter glycart privately owned biotechnology research company based schlieren zurich switzerland glycart reported part roche pharmaceuticals business segment purchase consideration paid million swiss francs allocated follows glycart acquisition net assets acquired millions chf carrying value carrying value prior acquisition upon acquisition goodwill intangible assets inprocess research development intangible assets core technology property plant equipment deferred income taxes cash net assets liabilities total goodwill recognised resulting premium paid acquisition represents synergies obtained groups existing business utilising acquired core technology intangible assets core technology amortised straightline basis years beginning august intangible assets inprocess research development amortised useful lives straightline basis beginning point available use subsequent acquisition glycart contributed net expense million swiss francs roche pharmaceuticals business result glycart acquired january revenues group would unchanged groups net income would lower million swiss francs compared reported results acquisitions igen february group acquired controlling interest igen international inc igen apublic company headquartered gaithersburg maryland usa acquisition gives group broad access human invitro diagnostics immunochemistry sector use electrochemiluminiscence ecl technology development elecsys product line acquisition approved extraordinary general meeting igens shareholders february cleared relevant antitrust authorities allocation total purchase consideration million swiss francs follows igen acquisition net assets acquired millions chf goodwill intangible assets deferred income taxes cash net assets liabilities total intangible assets amortised straightline basis years beginning march finance report roche group notes roche group consolidated financial statements financial income financing costs financial income millions chf year ended december gains sale equity securities losses sale equity securities dividend income gains losses equity derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities writedowns impairments longterm loans net interest income income debt securities foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total financial income financing costs millions chf year ended december interest expense amortisation discount debt instruments gains losses interest rate derivatives net time cost provisions total financing costs financing costs include net gains financial liabilities fairvaluethroughprofitorloss million swiss francs net loss million swiss francs included within gains losses interest rate derivatives net amount also includes change fair value attributable changes liabilities credit risk component change fair value due credit risk calculated comparing difference present value future cash flows bonds discounted using swap libor yield curve market prices bonds due decrease credit spread relative swap yield curve credit risk component resulted loss million swiss francs gain million swiss francs cumulative change fair value attributable change credit risk since issuance instruments gain million swiss francs interest expense liabilities fairvaluethroughprofitorloss million swiss francs million swiss francs exceptional income bond conversion redemption group converted redeemed certain debt instruments debt reduced million swiss francs total cash outflow million swiss francs net pretax gain million swiss francs resulted shown net gain disclosed separately income statement due materiality gain order fairly present groups results details given note finance report roche group notes roche group consolidated financial statements impact bond conversion redemption millions chf exceptional income bond conversion increase redemption reduction pretax debt cash outflow lyons iv us dollar exchangeable notes lyons iii us dollar exchangeable notes chameleon us dollar bonds lyons v us dollar exchangeable notes limited conversion preferred stock total income taxes income tax expenses millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total charge income taxes since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate millions chf average expected tax rate tax effect utilisation previously unrecognised tax losses nontaxable incomenondeductible expenses differences continuing businesses exceptional items effective tax rate profit income tax profit income tax tax taxes rate tax taxes rate roche excluding genentech chugai genentech chugai continuing businesses exceptional items effective tax rate amortisation goodwill major legal cases changes group organisation exceptional income bond conversion redemption groups effective tax rate finance report roche group notes roche group consolidated financial statements income tax assets liabilities millions chf current income taxes current income tax assets current income tax liabilities net current income tax asset liability deferred income taxes deferred income tax assets deferred income tax liabilities net deferred income tax asset liability deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances million swiss francs million swiss francs million swiss francs expire within three yearsand million swiss francs expire within five years remaining million swiss francs losses expire fifteen years deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable following items deferred income taxes movements recognised net assets liabilities millions chf property plant equipment restructuring temporary intangible assets provisions differences total year ended december net deferred income tax asset liability january previously reported changes accounting policy net deferred income tax asset liability january restated charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders acquisition igen discontinued businesses currency translation effects net deferred income tax asset liability december finance report roche group notes roche group consolidated financial statements property plant equipment restructuring temporary intangible assets provisions differences total year ended december net deferred income tax asset liability january charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders acquisition glycart currency translation effects net deferred income tax asset liability december discontinued businesses profit discontinued businesses millions chf consumer vitamins consumer vitamins health fine health fine otc chemicals total otc chemicals total segment revenues expenses operating profit exceptional items amortisation goodwill operating profit financing costs profit taxes income taxes business result gain loss disposal income taxes profit disposal profit discontinued businesses earnings per share nonvoting equity security discontinued businesses chf basic diluted equivalent amounts chf chf respectively assets liabilities discontinued businesses millions chf consumer vitamins consumer vitamins health fine health fine otc chemicals total otc chemicals total property plant equipment longterm assets current assets total assets provisions noncurrent liabilities current liabilities total liabilities net assets finance report roche group notes roche group consolidated financial statements significant cash flows discontinued businesses millions chf consumer vitamins consumer vitamins health fine health fine otc chemicals total otc chemicals total operating cash flows major legal cases proceeds disposal total significant cash inflows outflows divestment consumer health otc business july group announced sale roche consumer health global otc overthecounter medicines business bayer group sale also included five production facilities belonging roche pharmaceuticals business agreement bayer majority local businesses transferred bayer end december divestment bayer completed measured interms roche consumer health sales third parties divestment remaining completed terms agreement majority cash proceeds totalling million swiss francs transferred group january addition group received million swiss francs remaining part divestment completed july chugai announced sale otc business lion corporation sale completed effective december results consumer health otc business shown results include remaining part roche consumer health transferred bayer results include whole consumer health otc business period gain disposal consumer health otc business five roche pharmaceuticals production facilities millions chf net proceeds incidental transaction costs net assets disposed impairment restructuring charges accruals residual obligations retained roche group gain disposal discontinued businesses consumer health otc business roche pharmaceuticals business segment gain disposal table figures include preliminary assessments net debt adjustments purchase price mechanisms well initial calculations impairment restructuring charges accruals residual obligations retained roche group cash inflow disposal million swiss francs net cash balances million swiss francs held companies within consumer health otc business cash payments transaction costs million swiss francs terms agreement majority cash proceeds totalling million swiss francs transferred group january amount shown receivable december balance sheet cash inflow disposal totals million swissfrancs consists million francs received bayer january additional million swiss francs received parts business sold bayer finance report roche group notes roche group consolidated financial statements continuing businesses roche pharmaceuticals business segment five production facilities included sale bayer shown part roche pharmaceuticals results date disposal five production facilities transferred bayer end therefore included december balance sheet connection divestment roche consumer health roche pharmaceuticals business reassessed utilisation manufacturing facilities infrastructure service capacities addition terms agreement bayer roche pharmaceuticals business agreed certain interim manufacturing service obligations bayer result roche pharmaceuticals business recorded impairment charge based estimated net selling price shown table bayer transaction impact roche pharmaceuticals business segment millions chf net proceeds incidental transaction costs net assets five production facilities impairment charges restructuring charges accruals residual obligations retained roche pharmaceuticals business gain loss disposal roche pharmaceuticals business segment divestment vitamins fine chemicals business effective september receiving final regulatory approvals group completed sale global vitamins fine chemicals business vfc business dutch company dsm terms final purchase agreement dsm certain agreed purchase price adjustment mechanisms final amounts arising mechanisms approved group dsm additional cash transferred group dsm additional amounts recorded following sale vfc business certain assets liabilities vitamins fine chemicals division mainly associated vitamin case remain group described section vitamin case addition group given dsm certain indemnities respect remedial actions sites vfc business may required environmental laws arrangements put place regarding utilisation certain assets certain purchasing contracts well adopting dsm preferred supplier pharmaceutical ingredients one arrangements group guaranteed purchase period four years beginning january products sales value totalling million euros group reimburse dsm unutilised amounts arrangements consist certain residual obligations fully accrued expenses million swiss francs recorded million swiss francs mostly represent aftertax amortisation discounted liabilities vitamin case following settlement agreement us department justice may regarding pricing practices vitamin market overall settlement agreement class action suit brought us buyers bulk vitamins group recorded provisions respect vitamin case provisions groups best estimate time total liability may arise taking account currency movements time value money provisions legal fees recorded separately group recorded additional provisions based development litigation settlement negotiations us europe elsewhere finance report roche group notes roche group consolidated financial statements january district columbia circuit court appeals ruled class action litigation brought behalf nonus purchasers bulk vitamins group manufacturers nonus plaintiffs may bring claims us courts us antitrust laws alleged damages suffered transactions outside united states june supreme court united states nullified decision district columbia circuit court appeals supreme court remanded case lower court review alternative arguments might permit claims proceed united states remand june panel district columbia circuit court appeals ruled unanimously us courts jurisdiction plaintiffs claims affirmed initial dismissal complaint october plaintiffs petitioned us supreme court discretionary review january us supreme court issued order denying plaintiffs petition plaintiffs twenty five days date order seek reconsideration provisions recorded respect litigation group anticipate unfavourable outcome total payments year million swiss francs million swiss francs charged provisions previously recorded group seeking resolve remaining outstanding issues however timing final amounts involved uncertain remaining provisions recorded total million swiss francs based current litigation recent settlement agreements provisions considered shortterm cash outflows expected arise discounted time value money considered material case litigation negotiations progress possible ultimate liability may different amount provisions currently recorded part divestment vfc business liabilities respect vitamin case discussed remain roche group roche dsm signed indemnity cooperation agreement roche may provide dsm certain indemnities guarantees connection vitamin case employee benefits employee remuneration millions chf wages salaries social security costs postemployment benefits defined benefit plans postemployment benefits defined contribution plans equity compensation plans employee benefits total employees remuneration charges employee benefits included relevant expenditure line function employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits finance report roche group notes roche group consolidated financial statements pensions postemployment benefits employees covered retirement benefit plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic conditions countries employees employed major plans defined benefit plans largest located switzerland united states germany united kingdom japan postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states plans usually funded payments group employees trusts independent groups finances plan unfunded notably major defined benefit plans germany liability obligation recorded groups balance sheet defined benefit plans expenses recognised millions chf current service cost interest cost expected return plan assets net actuarial gains losses recognised past service cost gains losses curtailment gains losses settlement limit asset recognition total included employees remuneration actual return plan assets million swiss francs million swiss francs disclosed note second half chugai returned part employees pension fund japanese government resulted settlement gain million swiss francs accordance groups management organisational structure reported general administration expenses within corporate business segment effective january group apply ias revised employee benefits amongst matters therevised standard allows actuarial gains losses defined benefit plans recorded directly equity case adjustments arising limits recognition assets defined benefit plans also recorded directly equity revised standard requires retrospective application consequently group estimates restated results pretax expenses included employees remuneration approximately million swiss francs lower million swiss francs relates continuing businesses million swiss francs relates discontinued businesses defined benefit plans movements net recognised asset liability millions chf january consumer health otc business total expenses included employees remuneration contributions paid benefits paid unfunded plans currency translation effects december december group paid additional contribution million swiss francs one swiss post employment defined benefit plans payment included contributions paid table accounted part recognised surplus funded pension plans groups consolidated financial statements thereafter included actuarial calculation groups pension expenses balances finance report roche group notes roche group consolidated financial statements defined benefit plans amounts recognised balance sheet millions chf funded plans present value funded defined benefit obligations plan assets held trusts fair value plan assets excess deficit present value obligations unrecognised actuarial gains losses unrecognised past service costs net recognised asset liability funded defined benefit obligations unfunded plans present value unfunded defined benefit obligations unrecognised actuarial gains losses unrecognised past service costs recognised liability unfunded defined benefit obligations total net recognised asset liability funded unfunded defined benefit obligations reported surplus recognised noncurrent assets deficit recognised noncurrent liabilities total net recognised asset liability amounts include nonpension postemployment benefit schemes principally medical plans shown postemployment benefit plans millions chf present value defined benefit obligations plan assets held trusts fair value plan assets excess deficit present value obligations less unrecognised actuarial gains losses net recognised asset liability amounts recognised balance sheet postemployment defined benefit plans predominantly non current reported noncurrent assets liabilities included fair value assets funded plans zero groups nonvoting equity securities written call options total fair value million swiss francs zero group operates defined benefit schemes many countries actuarial assumptions vary based upon local economic social conditions range assumptions used actuarial valuations significant defined benefit plans countries stable currencies interest rates shown defined benefit plans actuarial assumptions weighted weighted average range average range discount rates projected rates remuneration growth expected rates return plan assets healthcare cost trend rate finance report roche group notes roche group consolidated financial statements employee stock options equity compensation benefits group operates several equity compensation plans including separate plans genentech chugai effective january group adopted ifrs sharebased payment amongst matters new standard requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading standard also requires retrospective application within certain transitional requirements details given note expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expense share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total operating expense equitysettled cashsettled cash inflow outflow equity compensation plans millions chf share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total cash inflow outflow equitysettled cashsettled finance report roche group notes roche group consolidated financial statements roche longterm group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan share option plans roche option plan awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note introduction roche longterm number options granted roche option plan significantly reduced eligible employees receive roche stocksettled stock appreciation rights instead roche option plan movement number options outstanding number weighted average number weighted average options exercise price chf options exercise price chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable weighted weighted weighted average average average number years remaining exercise number exercise year grant outstanding contractual life price chf exercisable price chf total genentech stock option plan genentech stock option plan adopted amended thereafter april genentechs shareholders approved equity incentive plan plans allow granting various stock options incentive stock options stock purchase rights employees directors consultants genentech incentive stock options stock purchase rights granted plan date options granted nontradable equitysettled awards tenyear duration vest phased basis four years subject continued employment genentech stock option plan movement number options outstanding number number options weighted average options weighted average thousands exercise price usd thousands exercise price usd outstanding january granted forfeited exercised expired outstanding december exercisable finance report roche group notes roche group consolidated financial statements genentech stock option plan terms options outstanding december options outstanding options exercisable weighted weighted number weighted average average number average range exercise prices outstanding years remaining exercise exercisable exercise usd thousands contractual life price usd thousands price usd total chugai stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai right entitles holder purchase chugai shares specified exercise price options nontradable equitysettled awards tenyear duration vest immediately upon grant chugai stock acquisition rights movement number rights outstanding number weighted average number weighted average options exercise price jpy options exercise price jpy outstanding january granted forfeited exercised expired outstanding december exercisable chugai stock acquisition rights terms rights outstanding december rights outstanding rights exercisable weighted weighted weighted average average average number years remaining exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy total finance report roche group notes roche group consolidated financial statements issues share options issues share options including methodology used calculate fair value main inputs valuation models described issues share option plans roche genentech stock chugai stock option plan option plan acquisition rights number options granted underlying equity roche nonvoting genentech common chugai shares equity securities stock blocks currency swiss francs us dollars japanese yen vesting period progressively progressively immediate years years contractual life years years years weighted average fair value options issued option pricing model used binomial binomial binomial inputs option pricing model share price grant date exercise price expected volatility expected dividend yield early exercise factor na expected exit rate volatility determined reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour chugai grants assumed awards would held full term length since none previously issued options ever exercised early equity compensation plans roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held nonvoting equity securities programme operational since october year cost plan million swiss francs million swiss francs reported within relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allows employees purchase genentechs common stock lower market value grant date purchase date total thousand shares genentech common stock purchased thousand shares resulting cash inflow million swiss francs million swiss francs year cost plan million swiss francs million swiss francs reported within relevant expenditure line function roche stocksettled stock appreciation rights introduction roche longterm group offers stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date options nontradable equitysettled awards seven year duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note finance report roche group notes roche group consolidated financial statements roche ssars movement number rights outstanding number weighted average number weighted average rights exercise price chf rights exercise price chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable weighted weighted weighted average average average number years remaining exercise number exercise year grant outstanding contractual life price chf exercisable price chf total weighted average fair value options granted calculated using binomial model inputs model consistent used roche option plan awards shown previously resulting weighted average fair value per right chf giving total fair value million swiss francs charged vesting period three years roche performance share plan group offers future nonvoting equity security awards boards discretion cash equivalent certain directors key senior managers programme established beginning effect three years board approved new threeyear cycle roche performance share plan psp operate amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholders return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors cycle total awards made nontradable equitysettled awards award result zero two nonvoting equity securities depending upon achievement performance targets allocated recipients february blackout period ended weighted average fair value options granted calculated using monte carlo simulation input parameters model covariance matrix roche individual companies peer group based threeyear history riskfree rate valuation also takes account defined rank performance structure determines payout psp resulting value per one unit psp cycle chf giving total fair value million swiss francs charged vesting period three years roche stock appreciation rights employees certain north american subsidiaries group receive stock appreciation rights sars part compensation sars nontradable cash settled awards may exercised vesting period one three years cash payment based upon amount market price groups american depositary receipts adrs point ofexercise exceeds strike price grant price issuance following implementation roche longterm see group plan award cashsettled sars awards made roche stock appreciation rights millions chf liability december intrinsic value vested rights december finance report roche group notes roche group consolidated financial statements roche stock appreciation rights terms rights outstanding december rights outstanding rights exercisable weighted weighted average average number exercise number exercise year grant outstanding expiry price usd exercisable price usd total fair value december calculated using binomial model inputs model adr price december usd exercise prices given table inputs consistent used roche option plan awards shown previously property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction improve land ments equipment progress total january cost accumulated depreciation impairment net book value year ended december january disposal consumer health otc business additions disposals transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january glycart acquisition disposal consumer health otc business additions disposals transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value finance report roche group notes roche group consolidated financial statements decrease property plant equipment million swiss francs disposal otc business consists assets transferred business million swiss francs impairment charge million swiss francs see note impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence could result shortened useful lives impairment leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs finance leases present value future minimum lease payments millions chf within one year one five years five years total present value minimum lease payments described note third quarter genentech bought finance lease obligations respect manufacturing facility vacaville california certain buildings south san francisco site carrying value lease obligations december million swiss francs operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs operating leases future minimum payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties though finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease receipts noncancellable leases millions chf present value future gross investment lease minimum lease payments within one year one five years five years total unearned finance income na na unguaranteed residual values na na net investment lease finance report roche group notes roche group consolidated financial statements accumulated allowance uncollectible minimum lease payments million swiss francs zero million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties though operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straight line basis december machinery equipment original cost million swiss francs net book value million swiss francs leased third parties future minimum lease payments non cancellable leases totalled million swiss francs million swiss francs due within one year million swiss francs due one five years million swiss francs due five years contingent rent recognised income capital commitments group capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs addition december genentech entered master lease agreement lease property south san francisco genentechs aggregate lease payments estimated approximately million us dollars goodwill goodwill movements carrying value assets millions chf january glycart acquisition igen acquisition acquisitions disposal consumer health otc business amortisation charge impairment charge currency translation effects december allocated following business segmentscashgenerating units roche pharmaceuticals genentech chugai diagnostics total accumulated impairment losses goodwill goodwill arising investments associated companies classified part investments associated companies see note effective january group implemented ifrs business combinations amongst matters new standard requires amortisation goodwill cease date implementation goodwill continue tested impairment standard requires prospective application standard applied goodwill amortisation expenses million swiss francs would recorded additional impairment would necessary finance report roche group notes roche group consolidated financial statements goodwill impairment testing groups reportable business segments cashgenerating units used testing goodwill pharmaceuticals division genentech chugai recoverable amount based fair value less costs sell determined reference publicly quoted share price genentech chugai shares goodwill roche pharmaceuticals business significant comparison groups total carrying amount goodwill diagnostics division recoverable amount used impairment testing based value use cash flow projections used based recent business plans approved management assume significant changes organisation division include managements latest estimates sales volume pricing production operating costs reflect past experience projected five years discount rate used based rate derived capital asset pricing model using data swiss us capital markets including swiss federal government year bonds us treasury year bonds smi sp indices adjusted pretax rate management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount intangible assets intangible assets movements carrying value assets millions chf patents licences trademarks intangible assets acquisition related total january cost accumulated amortisation impairment net book value year ended december january igen acquisition disposal consumer health otc business additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value finance report roche group notes roche group consolidated financial statements patents licences trademarks intangible assets acquisition related total year ended december january glycart acquisition additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated following business segmentscashgenerating units roche pharmaceuticals genentech chugai diagnostics total included roche pharmaceuticals business segment intangible assets carrying value million swiss francs remaining amortisation period years relate purchase group global rights kytril granisetron smithkline beecham diagnostics business segment includes intangible assets carrying value million swiss francs remaining amortisation period years relate acquisition corangeboehringermannheim intangible assets carrying value million swiss francs remaining amortisation period years relate acquisition igen group currently internally generated intangible assets development criteria recognition asset met impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment associated companies groups investments associated companies accounted using equity method goodwillarising investments associated companies classified part investments associated companies investments associated companies millions chf share net income balance sheet value total investments associated companies groups major investments associates basilea pharmaceutica ltd tripath imaging inc antisoma plc additional information companies given note material transactions group associated companies finance report roche group notes roche group consolidated financial statements financial longterm assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets prepaid employee benefits total longterm assets financial longterm assets held strategic purposes classified noncurrent available forsale investments mainly equity investments unquoted equity investments classified availableforsale generally measured cost fair value measured reliably primarily investments private biotechnology companies kept part groups strategic alliance efforts carrying value equity investments held cost million swiss francs million swiss francs effective interest rate heldtomaturity investments loans receivable comprise loans third parties term one year restricted cash includes million swiss francs cash investments pledged genentech connection city hope litigation see note equivalent amount classified current assets see note inventories inventories millions chf raw materials supplies work process finished goods intermediates less provision slowmoving obsolete inventory total inventories expenses relating inventories totalled million swiss francs million swiss francs million swiss francs expensed cost sales million swiss francs million swiss francs relating consumer health otc business expensed profit discontinued businesses million swiss francs accounts receivable accounts receivable millions chf trade accounts receivable notes receivable less provision doubtful accounts total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs bad debt expense million swiss francs million swiss francs finance report roche group notes roche group consolidated financial statements current assets current assets millions chf accrued interest income prepaid expenses derivative financial instruments restricted cash receivables total current assets restricted cash includes million swiss francs cash investments pledged genentech connection city hope litigation see note equivalent amount classified within financial longterm assets see note marketable securities marketable securities millions chf financial assets fairvaluethroughprofitorloss heldfortrading investments bonds debentures designated fairvaluethroughprofitorloss bonds debentures total financial assets fairvaluethroughprofitorloss availableforsale financial assets shares bonds debentures money market instruments time accounts three months total availableforsale financial assets total marketable securities marketable securities held fund management purposes classified current primarily denominated swiss francs euros us dollars pounds sterling investments held strategic purposes classified noncurrent see note shares consist primarily readily saleable equity securities bonds debentures millions chf average effective average effective contracted maturity amount interest rate amount interest rate within one year one five years five years total bonds debentures money market instruments generally fixed interest rates ranging depending upon currency denominated contracted mature within one year december finance report roche group notes roche group consolidated financial statements cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents restricted cash included within financial longterm assets see note current assets seenote accounts payable accounts payable millions chf trade accounts payable taxes payable accounts payable total accounts payable accrued current liabilities accrued current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities derivative financial instruments appropriate circumstances group uses derivative financial instruments part risk management trading strategies discussed note derivative financial instruments carried fair value themethods used determining fair value described note derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts swaps interest rate derivatives swaps derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement finance report roche group notes roche group consolidated financial statements described note group financial risk management policies foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks altered use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case thehedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described genentech hedged fixed term debt instruments interest rate swaps december instruments designated qualify fair value hedges recorded balance sheet liability fair value million swiss francs genentech nonus dollar cash flows future royalty income development expenses expected next one five years hedge part transaction exposure genentech enters derivative financial instruments options forward contracts genentech equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure genentech enters derivative financial instruments zero cost collars forward contracts december instruments designated qualify hedge accounting recorded balance sheet fair value million swiss francs matters also described genentechs annual report quarterly sec filings movements fair value reserve designated cash flow hedges included note provisions contingent liabilities provisions movements recognised liabilities millions chf environmental legal restructuring provisions provisions provisions total year ended december january previously reported changes accounting policy january restated disposal consumer health otc business vitamin case utilised year provisions additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion provisions noncurrent portions provisions total provisions finance report roche group notes roche group consolidated financial statements environmental legal restructuring provisions provisions provisions total year ended december january vitamin case utilised year major legal cases additional provisions created utilised year provisions additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion provisions noncurrent portions provisions total provisions expected outflow resources within one year one two years two three years three years total provisions environmental legal provisions provisions include million swiss francs million swiss francs environmental matters million swiss francs million swiss francs litigation including major legal cases thevitamin case provisions environmental matters include various separate environmental issues number countries approximately half preexisting companies acquired group nature amounts timing outflows difficult predict group estimates approximately half amount provided may result cash outflows next five years significant provisions discounted legal provisions consist mainly major legal cases described note vitamin case described note amounts timing uncertainties outflows discussed notes discount rates used remaining legal provisions account less balance consist number separate legal matters various group companies majority cash outflows expected occur within next one three years although dependent development various litigations significant provisions discounted major legal cases described note vitamin case described note litigation matters currently significant described finance report roche group notes roche group consolidated financial statements tamiflu development license agreement june gilead sciences inc gilead delivered group notice termination development license agreement tamiflu alleged material breach agreement november group gilead signed amended agreement settlement agreement ends dispute amongst matters amended agreement includes revised calculation royalty payments part settlement group paid gilead million us dollars retroactive royalty adjustments results cost sales includes royalty costs relating tamiflu sales including retroactive adjustments paid november based amended agreement settlement agreement relate sales made earlier general administration expenses include million swiss francs retrospective adjustments relating restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group remaining amounts mostly respect obligations towards former employees arising pharmaceuticals division restructuring previous restructuring plans timings cash outflows reasonably certain global basis shown table significant provisions discounted provisions provisions consist mostly claims arising trade various provisions group companies fit categories timings cash outflows nature uncertain best estimates shown table significant provisions discounted contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group engaged also subject physical risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable see also note respect vitamin case note respect major legal cases group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined thecollaboration agreements groups best estimate future commitments payments million swiss francs million swiss francs million swiss francs noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities finance report roche group notes roche group consolidated financial statements debt debt recognised liabilities millions chf debt instruments amounts due banks financial institutions capitalised lease obligations borrowings total debt reported longterm debt shortterm debt total debt debt repayment terms millions chf within one year one two years two three years three four years four five years five years total debt lyons zero coupon us dollar exchangeable notes see reflected due first year holders notes request group purchase notes fair value debt instruments billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt amounts due banks financial institutions interest rates amounts primarily denominated euros average approximately repayment dates three years million swiss francs million swiss francs due within one year finance report roche group notes roche group consolidated financial statements debt instruments recognised liabilities effective interest rates debt instruments millions chf effective interest rate european medium term note programme bonds due october principal million euros bonds due august principal million pounds sterling bonds due october principal million us dollars swiss franc bonds rodeo due march principal billion swiss francs us dollar bonds chameleon due july principal million us dollars zero coupon us dollar exchangeable notes lyons v due july principal billion us dollars japanese yen exchangeable bonds sumo due march principal billion japanese yen genentech senior notes senior notes due july principal million us dollars senior notes due july principal billion us dollars senior notes due july principal million us dollars japanese yen convertible bonds issued chugai series chugai pharmaceutical unsecured convertible bonds due september principal amount billion japanese yen billion japanese yen total debt instruments unamortised discount included carrying value debt instruments millions chf us dollar bonds sterling bonds zero coupon us dollar exchangeable notes japanese yen exchangeable bonds total unamortised discount fair value option disclosed note group applied fair value option three outstanding debt instruments group applying fair value hedge accounting past debt instruments european medium term note programme euro bonds chameleon us dollar bonds rodeo swiss franc bonds fair value option treatment based elimination accounting mismatch recognised hedging swaps reported fair value hedged bonds reported amortised cost difference carrying value principal amount debt instruments totals million swiss francs million swiss francs finance report roche group notes roche group consolidated financial statements issues new debt instruments july genentech completed private placement billion us dollars aggregate principal amount senior notes placement consists million us dollars senior notes due billion us dollars senior notes due million us dollars senior notes due senior notes contain certain restrictive covenants incurring property liens entering sale leaseback transactions cash inflows issues new debt instruments millions chf genentech senior notes senior notes issued july senior notes issued july senior notes issued july total cash inflows new issues year repayments redemptions conversions debt instruments redemption sumo japanese yen exchangeable bonds due date march group redeemed bonds original issue amount plus accrued original issue discount oid effective interest rate bonds cash outflow million swiss francs gain loss recorded redemption partial conversion repurchase lyons v us dollar exchangeable notes january group repurchased option bondholders total us dollars nominal value notes total consideration million us dollars million swiss francs equal carrying value notes total notes carrying value million swiss francs converted nonvoting equity securities notes repurchased called conversion represent number notes outstanding start year material impact financial statements partial conversion series chugai pharmaceutical unsecured convertible bonds bondswith face value billion japanese yen million swiss francs converted shares chugai groups percentage ownership chugai unaffected conversion group bonds convertible chugai shares mirror chugai outstanding third parties repayments redemptions conversions debt instruments group converted redeemed certain debt instruments debt reduced million swiss francs total cash outflow million swiss francs net pretax gain million swiss francs resulted shown note net gain reported exceptional item due itsmateriality transactions described conversion redemption lyons iv us dollar exchangeable notes march group exercised option call notes redemption april original issue amount plus accrued original issue discount oid effective interest rate notes period april notes principal amount million us dollars called conversion holders remaining notes redeemed cash april result conversion groups ownership genentech decreased group realised pretax gain million swiss francs part disposal interest genentech redemption remaining notes redemption lyons iii us dollar exchangeable notes april group exercised option call notes redemption may original issue amount plus accrued original issue discount oid effective interest rate notes notes principal amount billion us dollars redeemed cash group realised pretax loss million swiss francs early redemption notes finance report roche group notes roche group consolidated financial statements partial redemption chameleon us dollar bonds june group announced tender offer redemption chameleon bond effective interest rate bonds tender offer expired june pricing june point bonds principal amount million us dollars representing approximately outstanding bonds tendered redemption settlement made june group realised pretax loss million swiss francs partial early redemption bonds redemption limited conversion preferred stock mandatory redemption date november group redeemed remaining instruments original issue amount plus accrued interest effective interest rate instruments instruments principal amount million us dollars redeemed cash group realise gain loss redemption reassessment probable redemption date lyons v us dollar exchangeable notes effective september group reassessed likely future cash outflows instrument concluded wasappropriate consider first call date july probable date cash flows accordingly using effective interest rate method group recorded pretax expense million swiss francs increase debt amount reflects increase carrying value debt allow accreted value meet issue price plus accrued original issue discount oid july cash effect partial conversion series chugai pharmaceutical unsecured convertible bonds bonds face value billion japanese yen million swiss francs converted shares chugai groups percentage ownership chugai unaffected conversion group bonds convertible chugai shares mirror chugai outstanding third parties cash outflows repayments redemptions debt instruments millions chf sumo japanese yen exchangeable bonds lyons iv us dollar exchangeable notes lyons iii us dollar exchangeable notes chameleon us dollar bonds limited conversion preferred stock total cash outflows repayments redemptions year terms outstanding convertible debt instruments lyons v notes exchangeable nonvoting equity securities nes american depositary shares ads exchange ratio nes exchange adss per usd principal amount maturity notes group purchase note cash option holder july july july purchase price per usd principal amount notes usd usd usd respectively addition notes redeemable option group whole part time july issue price plus accrued original issue discount oid notes outstanding december exchanged would require nonvoting equity securities meet obligation series chugai pharmaceutical unsecured convertible bonds bond jpy par value convertible shares chugai conversion option bondholder may made time due date september bonds redeemable maturity issue price bonds outstanding december converted would require chugai shares exactly meet obligation groups percentage ownership chugai would affected conversion group bonds convertible chugai shares mirror chugai outstanding third parties finance report roche group notes roche group consolidated financial statements equity attributable roche shareholders changes equity attributable roche shareholders millions chf share equity retained fair value hedging translation year ended december capital instruments earnings reserve reserve reserve total january restated availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations income taxes items taken directly transferred equity minority interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december included movements translation reserve million swiss francs relating consumer health otc business included calculation gain disposal business see note finance report roche group notes roche group consolidated financial statements share equity retained fair value hedging translation year ended december capital instruments earnings reserve reserve reserve total january availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations income taxes items taken directly transferred equity minority interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december share capital december share capital roche holding ltd groups parent company consisted shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholders group pooled voting rights owns issued shares described note based information supplied group novartis international ltd basel affiliates participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates finance report roche group notes roche group consolidated financial statements dividends february shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board proposed dividends business year swiss francs per share nonvoting equity security subject approval annual general meeting february equity instruments holdings equity instruments equivalent number nonvoting equity securities december december nonvoting equity securities low exercise price options derivative instruments total equity instruments equity instruments recorded within equity original cost acquisition details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number nonvoting strike price market value equity securities maturity chf millions chf low exercise price options may nov derivative instruments feb feb total nonvoting equity securities low exercise price options mainly held potential conversion obligations may arise groups convertible debt instruments see note groups potential obligations employees roche option plan roche stocksettled appreciation rights see note covered call options exercisable time maturity group also holds residual number options purchased use groups previous option compensation scheme closed net cash inflow transactions equity instruments million swiss francs net cash inflow million swiss francs group holds none shares reserves fair value reserve fair value reserve represents cumulative net change fair value available forsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs finance report roche group notes roche group consolidated financial statements earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares non voting equity securities reduced weighted average number nonvoting equity securities held group period basic earnings per share nonvoting equity security continuing businesses group net income millions chf number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise convertible debt instruments employee stock option plans outstanding convertible debt instruments converted would lead reduction interest expense increase number shares may net dilutive effect earnings per share exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested genentech employee stock options would dilutive effect net income genentech positive diluted earnings per share nonvoting equity security reflects potential impacts dilutive effects earnings per share figures diluted earnings per share nonvoting equity security continuing businesses group net income millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf increase minority share group net income net tax assuming outstanding genentech stock options exercised millions chf net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf finance report roche group notes roche group consolidated financial statements minority interests changes equity attributable minority interests millions chf january restated net income recognised directly equity net income recognised income statement genentech chugai minority interests total net income recognised income statement total recognised income expense dividends paid minority shareholders equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december genentech chugai minority interests total minority interests related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares based information supplied shareholders group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeri group holds shares preceding year represents issued shares figure include shares without pooled voting rights held outside group individual members group mr andr hoffmann dr andreas oeri members board directors roche holding ltd capacity receive annual remuneration swiss francs addition mr hoffmann dr oeri receive swiss francs swiss francs respectively time expenses related membership board committees transactions group individual members shareholders group subsidiary associated companies listing major group subsidiaries associated companies included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associated companies finance report roche group notes roche group consolidated financial statements key management personnel members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration board directors chf compensation annual board committee remuneration members total executive director fb humer nonexecutive directors b gehrig r hnggi j bell p brabeckletmathe ljr de vink w frey hoffmann da julius oeri h teltschik total nonexecutive directors total remuneration board directors remuneration mr gehrig includes serving independent lead director vicechairman board remuneration mr hnggi includes serving vicechairman board connection acquisition glycart july see note group paid mr hnggi swiss francs consideration shareholding glycart equivalent amounts paid shareholders glycart thepurchase shareholdings remuneration nonexecutive members board directors totalled million swiss francs remuneration members executive committee chf expense annual salary bonus allowance total fb humer wm burns e hunziker ga keller jkc knowles h von prondzynski total annual salary amount dr humer includes swiss francs receives capacity member board directors described remuneration members executive committee totalled million swiss francs group pays social insurance contributions respect remuneration pays contributions pension postemployment benefits plans members executive committee members executive committee may also participate roche connect employee stock purchase plan see note finance report roche group notes roche group consolidated financial statements indirect benefits employer contributions members executive committee chf social insurance pensions roche connect fb humer wm burns e hunziker ga keller jkc knowles h von prondzynski total pension social insurance contributions paid group totalled million swiss francs roche longterm discussed note group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan rop members executive committee granted ssars rop awards roche performance share plan end members executive committee time awarded nonvoting equity securities fair value million swiss francs respect groups performance disclosed note board approved new threeyear cycle roche performance share plan operate total awards targeted members executive committee award result zero two nonvoting equity securities depending upon achievement performance targets allocated recipients end blackout period ended transactions members executive committee dr keller taken mortgage loan swiss francs pension fund f hoffmannla roche ltd interest rate pa theinterest rate loan fixed december postemployment benefit plans transactions group various postemployment defined benefit plans employees thegroup described note cash flow statement cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities including forexample taxes paid income bond conversion redemption cash generated operations millions chf net income add back nonoperating income expense income associated companies financial income financing costs exceptional income bond conversion redemption income taxes discontinued businesses operating profit finance report roche group notes roche group consolidated financial statements depreciation property plant equipment amortisation goodwill amortisation intangible assets impairment longterm assets changes group organisation major legal cases expenses defined benefit postemployment plans expenses equitysettled equity compensation plans adjustments cash generated continuing operations operating cash flows generated discontinued businesses cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects changes group organisation well cash generated groups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayments groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity interest dividends paid millions chf interest paid dividends paid total significant noncash transactions significant noncash transactions significant noncash investing financing transactions included conversion lyons iv notes genentech shares see note subsequent events significant events balance sheet date finance report roche group notes roche group consolidated financial statements subsidiaries associated companies listed companies share capital equity interest country company city mill switzerland roche holding ltd basel chf stock exchange swx zurich valor share valor genussscheine isin share ch isin genussscheine ch market capitalisation chf mill basilea pharmaceutica ltd basel chf stock exchange swx bio zurich nasdaq biotech valor isin ch market capitalisation chf mill usa genentech inc south san francisco usd stock exchange new york incorporated delaware isin us market capitalisation usd mill tripath imaging inc burlington usd stock exchange nasdaq nm isin us market capitalisation usd mill japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy mill great britain antisoma plc london gbp stock exchange london isin gb market capitalisation gbp mill nonlisted companies share capital equity interest country company city mill argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud syntex australia limited north sydney aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh ltd dhaka bdt belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur bermuda canadian pharmholding ltd hamilton gbp corange international ltd hamilton usd corange ltd hamilton usd roche capital management ltd hamilton usd roche financial investments ltd hamilton usd roche financial services ltd hamilton usd roche interfinance ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostics brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john usd chile productos farmoqumicos roche ltda santiago de chile clp china roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop finance report roche group notes roche group consolidated financial statements share capital equity interest country company city mill costa rica roche servicios sa san jos usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostics hvidovre dkk dominican productos roche dominicana sa santo domingo dop republic ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador usd estonia roche eesti tallinn eek finland roche oy espoo eur roche diagnostics oy espoo eur france cenexi sas fontenay sous bois eur roche diagnostics sa meylan eur roche sas neuillysurseine eur germany disetronic medical systems gmbh sulzbach eur galenus mannheim gmbh mannheim eur hoffmannla roche aktiengesellschaft grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics gmbh mannheim eur great britain roche diagnostics ltd lewes gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp greece roche hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq guernsey roche capital market international limited st peter port chf roche financial market limited st peter port chf honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche scientific company india private limited mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius lit luxembourg pharminvest sa luxembourg eur malaysia roche diagnostics malaysia sdn bhd kuala lumpur myr roche malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex de mxico sa de cv mexico city mxn lakeside de mxico sa de cv mexico city mxn productos roche sa de cv mexico city mxn syntex sa de cv mexico city mxn morocco roche sa casablanca mad netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics new zealand pty ltd auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche norge oslo nok roche diagnostics norge oslo nok pakistan roche pakistan ltd karachi pkr finance report roche group notes roche group consolidated financial statements share capital equity interest country company city mill panama productos roche interamericana sa panama city usd productos roche panam sa panama city pab roche capital corporation panama city usd syntex corporation panama city usd syntex puerto rico inc panama city usd technical development corp panama city usd peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc makati php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda lindaavelha eur romania roche romania srl bucharest ron russia roche moscow ltd moscow rub serbia roche doo beograd belgrade eur montenegro singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk slovenia roche doo pharmaceutical company ljubljana sit south africa roche products proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf disetronic licensing ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche instrument center ltd rotkreuz chf roche capital market ltd basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try uruguay roche international ltd montevideo uyu sapac corporation ltd montevideo uyu usa disetronic medical systems inc st paul usd hoffmannla roche inc nutley usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostics corporation indianapolis usd roche finance america inc wilmington usd roche finance usa inc wilmington usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche palo alto llc palo alto usd venezuela productos roche sa caracas veb share capital less local currency units finance report report group auditors report group auditors annual general meeting roche holding ltd basel group auditors audited consolidated financial statements income statement balance sheet cashflow statement statement recognised income expense statement changes equity notes pages roche holding ltd year ended december consolidated financial statements responsibility board directors responsibility express opinion consolidated financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance swiss auditing standards international standards auditing isa require audit planned performed obtain reasonable assurance whether consolidated financial statements free material misstatement examined test basis evidence supporting amounts disclosures consolidated financial statements also assessed accounting principles used significant estimates made overall consolidated financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law recommend consolidated financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems auditor charge basel january finance report multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable minority interests additions property plant equipment personnel number employees end year key ratios net income sales net income equity research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf cash warrants addition dividend adjusted chf b cash warrants addition dividend unadjusted chf b information table stated reported changes accounting policies arising changes international financial reporting standards stock split applied retrospectively net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data b assuming centenary warrants held final exercise date c dividend include special dividend relating spinoff fragrances flavours division dividend proposed board directors finance report roche group multiyear overview c c finance report roche group multiyear overview sales division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals total sales geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals corporate total additions property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total finance report supplementary net income eps information groups basic diluted earnings per share information given note consolidated financial statements supplementary eps information given net income exceptional items also core net income additionally excludes amortisation intangible assets related impacts income taxes minority interests profit continuing businesses exceptional items core net income millions chf year ended december profit continuing businesses goodwill amortisation major legal cases income taxes changes group organisation income taxes exceptional financial income income taxes profit continuing businesses exceptional items minority interests profit continuing businesses goodwill amortisation net income attributable roche shareholders continuing businesses exceptional items amortisation intangible assets income taxes minority interest core net income eps continuing businesses exceptional items core eps eps continuing businesses exceptional items core eps year ended december net income attributable roche shareholders millions chf elimination interest expense net tax convertible debt instruments dilutive increase minority share net income net tax assuming outstanding genentech chugai stock options exercised net income used calculate diluted earnings per share per share information millions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed conversion convertible debt instruments dilutive adjustment assumed exercise equity compensation plans dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share earnings per share dilutedchf finance report roche securities price development share chf roche share adjusted swiss market index rebased price development nonvoting equ ity security genussschein chf roche nonvoting equity security adjusted swiss market index rebased price development american depositary receipt adr usd roche adr adjusted sp index rebased two roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july information tables restated stock split roche shares nonvoting equity securities genussscheine effective may change ratio adrs effective january finance report roche group roche securities number shares nonvoting equity securitiesa number shares nominal value chf number nonvoting equity securities genussscheine nominal value total data per share nonvoting equity security chf net income equity dividend c stock price shareb high low yearend stock price nonvoting equity security genussscheinb high low yearend market capitalisation millions chf yearend key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg ro sw rog vx rhhby us swx swiss exchange ro rog finance report roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income gain disposal participations income group companies income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year finance report roche holding ltd basel financial statements balance sheet december millions chf noncurrent assets participations longterm loans group companies total noncurrent assets current assets shortterm loans group companies accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions loans group companies total noncurrent liabilities current liabilities accounts payable group companies unrealised foreign currency gains liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value finance report notes financial statements general financial statements roche holding ltd basel prepared accordance provisions swiss law valuation methods translation foreign currencies marketable securities reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred details specific items taxes tax charge includes corporate income capital taxes withholding taxes stamp duty equity movement recognised amounts millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity non voting equity securities genussscheine part share capital confer voting rights however nonvoting equity security genussschein confer rights one shares participate available earnings remaining proceeds liquidation following repayment share capital guarantees within framework european medium term note emtn programme company issued guarantees favour group companies amounting million swiss francs previous year million swiss francs finance report roche holding ltd basel notes financial statements time preparing balance sheet risks arising contingent liabilities discernible convertibles options reference made notes consolidated financial statements equity instruments reference made notes consolidated financial statements pledged assets december assets pledged security companys commitments previous year million swiss francs participations major participations listed pages important shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting february information available company previous year shares shareholders group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeria previous year shares participation novartis international ltd basel including affiliates thereofb information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis international ltd basel finance report appropriation available earnings proposals annual general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account finance report report statutory auditors report statutory auditors annual general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd year ended december financial statements responsibility board directors responsibility express opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance swiss auditing standards require audit planned performed obtain reasonable assurance whether financial statements free material misstatement examined test basis evidence supporting amounts disclosures financial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit provides reasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems auditor charge basel january finance report published cautionary statement regarding forward fhoffmannla roche ltd looking statements baselswitzerland annual report contains certain forwardlook tel ing statements forwardlooking statements fax may identified words believes expects anticipates projects intends media office seeks estimates future similar expressions corporate communications discussion among things strategy baselswitzerland goals plans intentions various factors may tel cause actual results differ materially future fax reflected forwardlooking statements contained annual report among others investor relations pricing product initiatives competitors baselswitzerland legislative regulatory developments tel economic conditions delay inability fax obtaining regulatory approvals bringing prod ucts market fluctuations currency world wide web exchange rates general financial market condi httpwwwrochecom tions uncertainties discovery develop ment marketing new products new uses order publications existing products including without limitation tel negative results ofclinical trials research projects fax unexpected sideeffects pipeline marketed emailbaselwebmasterrochecom products increased government pricing pres sures interruptions production loss orinability obtain adequate protection intel lectual property rights litigation loss key executives employeesand adverse publicity news coverage statement regarding earnings per share growth profit forecast inter preted mean roches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share ofroche next annual general meeting february trademarks mentioned enjoy legal protection roche annual report published german original language english roche annual report issued f hoffmannla roche ltd basel corporate communications finance report